Resistance detection and re-treatment options in hepatitis C virus-related chronic liver diseases after DAA-treatment failure

go back to reference Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis. 2000;20:47–55.CrossRef Poynard T, Ratziu V, Benmanov Y, Di Martino V, Bedossa P, Opolon P. Fibrosis in patients with chronic hepatitis C: detection and significance. Semin Liver Dis. 2000;20:47–55.CrossRef

go back to reference Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825–32.CrossRef Poynard T, Bedossa P, Opolon P. Natural history of liver fibrosis progression in patients with chronic hepatitis C. Lancet. 1997;349:825–32.CrossRef

go back to reference Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17–35.CrossRef Alter HJ, Seeff LB. Recovery, persistence, and sequelae in hepatitis C virus infection: a perspective on long-term outcome. Semin Liver Dis. 2000;20:17–35.CrossRef

go back to reference Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, Boemio A, Nobili B, Pasquale G, Maione S, Adinolfi LE, Perrone L, Sagnelli E, Miraglia Del Giudice E, Rossi F. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12:334–40. https://doi.org/10.1016/j.cgh.2013.05.008.CrossRefPubMed Coppola N, Zampino R, Bellini G, Macera M, Marrone A, Pisaturo M, Boemio A, Nobili B, Pasquale G, Maione S, Adinolfi LE, Perrone L, Sagnelli E, Miraglia Del Giudice E, Rossi F. Association between a polymorphism in cannabinoid receptor 2 and severe necroinflammation in patients with chronic hepatitis C. Clin Gastroenterol Hepatol. 2014;12:334–40. https://​doi.​org/​10.​1016/​j.​cgh.​2013.​05.​008.CrossRefPubMed

go back to reference Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.CrossRef Shepard CW, Finelli L, Alter MJ. Global epidemiology of hepatitis C virus infection. Lancet Infect Dis. 2005;5:558–67.CrossRef

go back to reference Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52.CrossRef Lauer GM, Walker BD. Hepatitis C virus infection. N Engl J Med. 2001;345:41–52.CrossRef

go back to reference Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12:S2. https://doi.org/10.1186/1471-2334-12-S2-S2.CrossRefPubMedPubMedCentral Zaltron S, Spinetti A, Biasi L, Baiguera C, Castelli F. Chronic HCV infection: epidemiological and clinical relevance. BMC Infect Dis. 2012;12:S2. https://​doi.​org/​10.​1186/​1471-2334-12-S2-S2.CrossRefPubMedPubMedCentral

go back to reference Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42. https://doi.org/10.1002/hep.26141.CrossRef Mohd Hanafiah K, Groeger J, Flaxman AD, Wiersma ST. Global epidemiology of hepatitis C virus infection: new estimates of age-specific antibody to HCV seroprevalence. Hepatology. 2013;57:1333–42. https://​doi.​org/​10.​1002/​hep.​26141.CrossRef

go back to reference Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis United States. 56th ed. Atlanta: Centers for Disease Control and Prevention; 2005. p. 1–24. Centers for Disease Control and Prevention. Surveillance for acute viral hepatitis United States. 56th ed. Atlanta: Centers for Disease Control and Prevention; 2005. p. 1–24.

go back to reference Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, Babudieri S, Toti M, Francavilla R, Ancarani F, Antonucci G, Scotto G, Di Marco V, Pastore G, Stroffolini T. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis. 2006;43:1154–9. https://doi.org/10.1086/507640.CrossRefPubMed Santantonio T, Medda E, Ferrari C, Fabris P, Cariti G, Massari M, Babudieri S, Toti M, Francavilla R, Ancarani F, Antonucci G, Scotto G, Di Marco V, Pastore G, Stroffolini T. Risk factors and outcome among a large patient cohort with community-acquired acute hepatitis C in Italy. Clin Infect Dis. 2006;43:1154–9. https://​doi.​org/​10.​1086/​507640.CrossRefPubMed

go back to reference Corey KE, Ross AS, Wurcel A, Schulze Zur Wiesch J, Kim AY, Lauer GM, Chung RT. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006;4:1278–82. https://doi.org/10.1016/j.cgh.2006.06.026.CrossRefPubMedPubMedCentral Corey KE, Ross AS, Wurcel A, Schulze Zur Wiesch J, Kim AY, Lauer GM, Chung RT. Outcomes and treatment of acute hepatitis C virus infection in a United States population. Clin Gastroenterol Hepatol. 2006;4:1278–82. https://​doi.​org/​10.​1016/​j.​cgh.​2006.​06.​026.CrossRefPubMedPubMedCentral

go back to reference Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48:148–62.CrossRef Esteban JI, Sauleda S, Quer J. The changing epidemiology of hepatitis C virus infection in Europe. J Hepatol. 2008;48:148–62.CrossRef

go back to reference Martinez-Bauer E, Forns X, Armelles M, Planas R, Solà R, Vergara M, Fàbregas S, Vega R, Salmerón J, Diago M, Sánchez-Tapias JM, Bruguera M, Spanish Acute HCV Study Group. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol. 2008;48:20–7. https://doi.org/10.1016/j.jhep.2007.07.031.CrossRefPubMed Martinez-Bauer E, Forns X, Armelles M, Planas R, Solà R, Vergara M, Fàbregas S, Vega R, Salmerón J, Diago M, Sánchez-Tapias JM, Bruguera M, Spanish Acute HCV Study Group. Hospital admission is a relevant source of hepatitis C virus acquisition in Spain. J Hepatol. 2008;48:20–7. https://​doi.​org/​10.​1016/​j.​jhep.​2007.​07.​031.CrossRefPubMed

go back to reference Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59:765–73. https://doi.org/10.1093/cid/ciu447.CrossRef Benova L, Mohamoud YA, Calvert C, Abu-Raddad LJ. Vertical transmission of hepatitis C virus: systematic review and meta-analysis. Clin Infect Dis. 2014;59:765–73. https://​doi.​org/​10.​1093/​cid/​ciu447.CrossRef

go back to reference Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, Nishioka K, Purcell RH, Alter HJ. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med. 1991;115:367–9.CrossRef Kiyosawa K, Sodeyama T, Tanaka E, Nakano Y, Furuta S, Nishioka K, Purcell RH, Alter HJ. Hepatitis C in hospital employees with needlestick injuries. Ann Intern Med. 1991;115:367–9.CrossRef

go back to reference Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Houghton Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral-hepatitis genome. Science. 1989;244:359–62.CrossRef Choo QL, Kuo G, Weiner AJ, Overby LR, Bradley DW, Houghton M. Houghton Isolation of a cDNA clone derived from a blood-borne non-A, non-B viral-hepatitis genome. Science. 1989;244:359–62.CrossRef

go back to reference Ruta S, Cernescu C. Injecting drug use: a vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol. 2015;21:10811–23. https://doi.org/10.3748/wjg.v21.i38.10811.CrossRefPubMedPubMedCentral Ruta S, Cernescu C. Injecting drug use: a vector for the introduction of new hepatitis C virus genotypes. World J Gastroenterol. 2015;21:10811–23. https://​doi.​org/​10.​3748/​wjg.​v21.​i38.​10811.CrossRefPubMedPubMedCentral

go back to reference Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol. 1993;67:4665–75.PubMedPubMedCentral Hijikata M, Mizushima H, Akagi T, Mori S, Kakiuchi N, Kato N, Tanaka T, Kimura K, Shimotohno K. Two distinct proteinase activities required for the processing of a putative nonstructural precursor protein of hepatitis C virus. J Virol. 1993;67:4665–75.PubMedPubMedCentral

go back to reference Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov. 2002;1:911–6. https://doi.org/10.1038/nrd942.CrossRefPubMed Bartenschlager R. Hepatitis C virus replicons: potential role for drug development. Nat Rev Drug Discov. 2002;1:911–6. https://​doi.​org/​10.​1038/​nrd942.CrossRefPubMed

go back to reference Koch JO, Bartenschlager R. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. J Virol. 1999;73:7138–46.PubMed Koch JO, Bartenschlager R. Modulation of hepatitis C virus NS5A hyperphosphorylation by nonstructural proteins NS3, NS4A, and NS4B. J Virol. 1999;73:7138–46.PubMed

go back to reference Hanoulle X, Verdegem D, Badillo A, Wieruszeski JM, Penin F, Lippens G. Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. Biochem Biophys Res Commun. 2009;381:634–8.CrossRef Hanoulle X, Verdegem D, Badillo A, Wieruszeski JM, Penin F, Lippens G. Domain 3 of non-structural protein 5A from hepatitis C virus is natively unfolded. Biochem Biophys Res Commun. 2009;381:634–8.CrossRef

go back to reference Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318–27.CrossRef Smith DB, Bukh J, Kuiken C, Muerhoff AS, Rice CM, Stapleton JT, Simmonds P. Expanded classification of hepatitis C virus into 7 genotypes and 67 subtypes: updated criteria and genotype assignment web resource. Hepatology. 2014;59:318–27.CrossRef

go back to reference Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:45–57.CrossRef Gower E, Estes C, Blach S, Razavi-Shearer K, Razavi H. Global epidemiology and genotype distribution of the hepatitis C virus infection. J Hepatol. 2014;61:45–57.CrossRef

go back to reference Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74. https://doi.org/10.1002/hep.22759.CrossRefPubMed Ghany MG, Strader DB, Thomas DL, Seeff LB, American Association for the Study of Liver Diseases. Diagnosis, management, and treatment of hepatitis C: an update. Hepatology. 2009;49:1335–74. https://​doi.​org/​10.​1002/​hep.​22759.CrossRefPubMed

go back to reference Coppola N, Martini S, Pisaturo M, Sagnelli C, Filippini P, Sagnelli E. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virol. 2015;4:1–12. https://doi.org/10.5501/wjv.v4.i1.1 (review).CrossRefPubMedPubMedCentral Coppola N, Martini S, Pisaturo M, Sagnelli C, Filippini P, Sagnelli E. Treatment of chronic hepatitis C in patients with HIV/HCV coinfection. World J Virol. 2015;4:1–12. https://​doi.​org/​10.​5501/​wjv.​v4.​i1.​1 (review).CrossRefPubMedPubMedCentral

go back to reference Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E. Hepatitis C virus markers in infection by hepatitis C virus: in the era of directly acting antivirals. World J Gastroenterol. 2015;21:10749–59. https://doi.org/10.3748/wjg.v21.i38.10749.CrossRefPubMedPubMedCentral Coppola N, Pisaturo M, Zampino R, Macera M, Sagnelli C, Sagnelli E. Hepatitis C virus markers in infection by hepatitis C virus: in the era of directly acting antivirals. World J Gastroenterol. 2015;21:10749–59. https://​doi.​org/​10.​3748/​wjg.​v21.​i38.​10749.CrossRefPubMedPubMedCentral

go back to reference Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis. 2012;12:357. https://doi.org/10.1186/1471-2334-12-357.CrossRefPubMedPubMedCentral Coppola N, Pisaturo M, Tonziello G, Sagnelli C, Sagnelli E, Angelillo IF. Efficacy of pegylated interferon α-2a and α-2b in patients with genotype 1 chronic hepatitis C: a meta-analysis. BMC Infect Dis. 2012;12:357. https://​doi.​org/​10.​1186/​1471-2334-12-357.CrossRefPubMedPubMedCentral

go back to reference Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One. 2014;9:e94542. https://doi.org/10.1371/journal.pone.0094542 (eCollection 2014).CrossRefPubMedPubMedCentral Coppola N, Pisaturo M, Sagnelli C, Sagnelli E, Angelillo IF. Peg-interferon plus ribavirin with or without boceprevir or telaprevir for HCV genotype 1: a meta-analysis on the role of response predictors. PLoS One. 2014;9:e94542. https://​doi.​org/​10.​1371/​journal.​pone.​0094542 (eCollection 2014).CrossRefPubMedPubMedCentral

go back to reference Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis. 2010;42:81–91. https://doi.org/10.1016/j.dld.2009.08.001.CrossRef Italian Association for the Study of the Liver; Italian Society of Infectious, Tropical Diseases; Italian Society for the Study of Sexually Transmitted Diseases. Practice guidelines for the treatment of hepatitis C: recommendations from an AISF/SIMIT/SIMAST Expert Opinion Meeting. Dig Liver Dis. 2010;42:81–91. https://​doi.​org/​10.​1016/​j.​dld.​2009.​08.​001.CrossRef

go back to reference European Association of the Study of the Liver. European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2011;32(Suppl 1):2–8. https://doi.org/10.1111/j.1478-3231.2011.02703.x.CrossRef European Association of the Study of the Liver. European Association of the Study of the Liver hepatitis C virus clinical practice guidelines. Liver Int. 2011;32(Suppl 1):2–8. https://​doi.​org/​10.​1111/​j.​1478-3231.​2011.​02703.​x.CrossRef

go back to reference van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.CrossRef van der Meer AJ, Veldt BJ, Feld JJ, Wedemeyer H, Dufour JF, Lammert F, Duarte-Rojo A, Heathcote EJ, Manns MP, Kuske L, Zeuzem S, Hofmann WP, de Knegt RJ, Hansen BE, Janssen HL. Association between sustained virological response and all-cause mortality among patients with chronic hepatitis C and advanced hepatic fibrosis. JAMA. 2012;308:2584–93.CrossRef

go back to reference Deterding K, Hoener zu Siederdissen C, Port K, Solbach P, Sollik L, Kirschner J, Mix C, Cornberg J, Worzala D, Mix H, Manns MP, Cornberg M, Wedemeyer H. Improvement of liver function parameters in advanced HCV associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther. 2015;42:889–901.CrossRef Deterding K, Hoener zu Siederdissen C, Port K, Solbach P, Sollik L, Kirschner J, Mix C, Cornberg J, Worzala D, Mix H, Manns MP, Cornberg M, Wedemeyer H. Improvement of liver function parameters in advanced HCV associated liver cirrhosis by IFN-free antiviral therapies. Aliment Pharmacol Ther. 2015;42:889–901.CrossRef

go back to reference AASLD-IDSA HCV Guidance. Recommendations for testing, managing, and treating hepatitis C. https://www.hcvguidelines.org. Accessed 1 June 2018. AASLD-IDSA HCV Guidance. Recommendations for testing, managing, and treating hepatitis C. https://​www.​hcvguidelines.​org. Accessed 1 June 2018.

go back to reference EASL Recommendations on Treatment of Hepatitis C. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C. J Hepatol 2017. 2016;66:153–94. EASL Recommendations on Treatment of Hepatitis C. Hepatitis C guidance: AASLD-IDSA recommendations for testing, managing, and treating hepatitis C. J Hepatol 2017. 2016;66:153–94.

go back to reference Coppola N, De Pascalis S, Messina V, Di Caprio G, Martini S, de Stefano G, Starace M, Stornaiuolo G, Stanzione M, Ascione T, Minichini C, Sangiovanni V, Zampino R, Calò F, Rinaldi L, Persico M, Federico A, Buonomo AR, Borgia G, Gaeta GB, Filippini P, Gentile I. ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens. Antivirus Ther. 2017;22:551–8. https://doi.org/10.3851/IMP3134.CrossRef Coppola N, De Pascalis S, Messina V, Di Caprio G, Martini S, de Stefano G, Starace M, Stornaiuolo G, Stanzione M, Ascione T, Minichini C, Sangiovanni V, Zampino R, Calò F, Rinaldi L, Persico M, Federico A, Buonomo AR, Borgia G, Gaeta GB, Filippini P, Gentile I. ITPase activity modulates the severity of anaemia in HCV-related cirrhosis treated with ribavirin-containing interferon-free regimens. Antivirus Ther. 2017;22:551–8. https://​doi.​org/​10.​3851/​IMP3134.CrossRef

go back to reference Caudai C, Materazzi A, Saladini F, Di Giambenedetto S, Torti C, Ricciardi B, Rossetti B, Almi P, De Luca A, Zazzi M. Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clin Microbiol Infect. 2017. https://doi.org/10.1016/j.cmi.2017.08.003.CrossRefPubMed Caudai C, Materazzi A, Saladini F, Di Giambenedetto S, Torti C, Ricciardi B, Rossetti B, Almi P, De Luca A, Zazzi M. Natural NS5A inhibitor resistance associated substitutions in hepatitis C virus genotype 1 infected patients from Italy. Clin Microbiol Infect. 2017. https://​doi.​org/​10.​1016/​j.​cmi.​2017.​08.​003.CrossRefPubMed

go back to reference Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, et al. NS5A resistance-associated substitutions inpatients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66:910–918.CrossRef Zeuzem S, Mizokami M, Pianko S, Mangia A, Han KH, Martin R, et al. NS5A resistance-associated substitutions inpatients with genotype 1 hepatitis C virus: prevalence and effect on treatment outcome. J Hepatol. 2017;66:910–918.CrossRef

go back to reference AASLD-IDSA. 2018. Recommendations for testing, managing, and treating hepatitis C. http://www.hcvguidelines.org. Accessed 24 Oct 2017. AASLD-IDSA. 2018. Recommendations for testing, managing, and treating hepatitis C. http://​www.​hcvguidelines.​org. Accessed 24 Oct 2017.

go back to reference Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Update. 2018;37:17–39. https://doi.org/10.1016/j.drup.2018.01.004 (Epub 2018 Feb 21. Review. Erratum in: Drug Resist Update).CrossRef Sorbo MC, Cento V, Di Maio VC, Howe AYM, Garcia F, Perno CF, Ceccherini-Silberstein F. Hepatitis C virus drug resistance associated substitutions and their clinical relevance: update 2018. Drug Resist Update. 2018;37:17–39. https://​doi.​org/​10.​1016/​j.​drup.​2018.​01.​004 (Epub 2018 Feb 21. Review. Erratum in: Drug Resist Update).CrossRef

go back to reference Wei B, Kang J, Kibukawa M, Chen L, Qiu P, Lahser F, Marton M, Levitan D. Development and validation of a template-independent next-generation sequencing assay for detecting low-level resistance-associated variants of hepatitis C virus. J Mol Diagn. 2016;18(5):643–656. https://doi.org/10.1016/j.jmoldx.2016.04.001. (Epub 2016 Jul 7).CrossRefPubMed Wei B, Kang J, Kibukawa M, Chen L, Qiu P, Lahser F, Marton M, Levitan D. Development and validation of a template-independent next-generation sequencing assay for detecting low-level resistance-associated variants of hepatitis C virus. J Mol Diagn. 2016;18(5):643–656. https://​doi.​org/​10.​1016/​j.​jmoldx.​2016.​04.​001. (Epub 2016 Jul 7).CrossRefPubMed

go back to reference Wang W, Ren Y, Lu Y, Xu Y, Crosby SD, Di Bisceglie AM, Fan X. Template-dependent multiple displacement amplification for profiling human circulating RNA. Biotechniques. 2017;63(1):21–27. https://doi.org/10.2144/000114566.CrossRefPubMedPubMedCentral Wang W, Ren Y, Lu Y, Xu Y, Crosby SD, Di Bisceglie AM, Fan X. Template-dependent multiple displacement amplification for profiling human circulating RNA. Biotechniques. 2017;63(1):21–27. https://​doi.​org/​10.​2144/​000114566.CrossRefPubMedPubMedCentral

go back to reference Paolucci S, Fiorina L, Piralla A, Gulminetti R, Stefano Novati S, Giorgio Barbarini G, Paolo Sacchi P, Mrta Gatti M, Luca Dossena L, Baldanti F. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J. 2012;9:245. https://doi.org/10.1186/1743-422X-9-245.CrossRefPubMedPubMedCentral Paolucci S, Fiorina L, Piralla A, Gulminetti R, Stefano Novati S, Giorgio Barbarini G, Paolo Sacchi P, Mrta Gatti M, Luca Dossena L, Baldanti F. Naturally occurring mutations to HCV protease inhibitors in treatment-naive patients. Virol J. 2012;9:245. https://​doi.​org/​10.​1186/​1743-422X-9-245.CrossRefPubMedPubMedCentral

go back to reference Costantino A, Spada E, Equestre M, Bruni R, Tritarelli E, Coppola N, Sagnelli C, Sagnelli E, Ciccaglione AR. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naive patients with chronic hepatitis C. Virol J. 2015;12:186. https://doi.org/10.1186/s12985-015-0414-1.CrossRefPubMedPubMedCentral Costantino A, Spada E, Equestre M, Bruni R, Tritarelli E, Coppola N, Sagnelli C, Sagnelli E, Ciccaglione AR. Naturally occurring mutations associated with resistance to HCV NS5B polymerase and NS3 protease inhibitors in treatment-naive patients with chronic hepatitis C. Virol J. 2015;12:186. https://​doi.​org/​10.​1186/​s12985-015-0414-1.CrossRefPubMedPubMedCentral

go back to reference Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447–62. https://doi.org/10.1053/j.gastro.2009.11.055.CrossRefPubMed Sarrazin C, Zeuzem S. Resistance to direct antiviral agents in patients with hepatitis C virus infection. Gastroenterology. 2010;138:447–62. https://​doi.​org/​10.​1053/​j.​gastro.​2009.​11.​055.CrossRefPubMed

go back to reference Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013;57:221–9. https://doi.org/10.1093/cid/cit226.CrossRefPubMed Sullivan JC, De Meyer S, Bartels DJ, Dierynck I, Zhang EZ, Spanks J, Tigges AM, Ghys A, Dorrian J, Adda N, Martin EC, Beumont M, Jacobson IM, Sherman KE, Zeuzem S, Picchio G, Kieffer TL. Evolution of treatment-emergent resistant variants in telaprevir phase 3 clinical trials. Clin Infect Dis. 2013;57:221–9. https://​doi.​org/​10.​1093/​cid/​cit226.CrossRefPubMed

go back to reference US Food and Drug Administration. Simeprevir product insert. 2013. http://www.accessdata.fda.gov/drugsatfda_docs/label/2013/205123s001lbl.pdf. Accessed 24 May 2018. US Food and Drug Administration. Simeprevir product insert. 2013. http://​www.​accessdata.​fda.​gov/​drugsatfda_​docs/​label/​2013/​205123s001lbl.​pdf. Accessed 24 May 2018.

go back to reference McPhee F, Friborg J, Levine S, Chen C, Falk P, Yu F, Hernandez D, Lee MS, Chaniewski S, Sheaffer AK, Pasquinelli C. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother. 2012;56:3670–81. https://doi.org/10.1128/AAC.00308-12.CrossRefPubMedPubMedCentral McPhee F, Friborg J, Levine S, Chen C, Falk P, Yu F, Hernandez D, Lee MS, Chaniewski S, Sheaffer AK, Pasquinelli C. Resistance analysis of the hepatitis C virus NS3 protease inhibitor asunaprevir. Antimicrob Agents Chemother. 2012;56:3670–81. https://​doi.​org/​10.​1128/​AAC.​00308-12.CrossRefPubMedPubMedCentral

go back to reference Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146:420–9. https://doi.org/10.1053/j.gastro.2013.10.057.CrossRefPubMed Everson GT, Sims KD, Rodriguez-Torres M, Hézode C, Lawitz E, Bourlière M, Loustaud-Ratti V, Rustgi V, Schwartz H, Tatum H, Marcellin P, Pol S, Thuluvath PJ, Eley T, Wang X, Huang SP, McPhee F, Wind-Rotolo M, Chung E, Pasquinelli C, Grasela DM, Gardiner DF. Efficacy of an interferon- and ribavirin-free regimen of daclatasvir, asunaprevir, and BMS-791325 in treatment-naive patients with HCV genotype 1 infection. Gastroenterology. 2014;146:420–9. https://​doi.​org/​10.​1053/​j.​gastro.​2013.​10.​057.CrossRefPubMed

go back to reference Zeuzem Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14. https://doi.org/10.1056/NEJMoa1401561.CrossRefPubMed Zeuzem Jacobson IM, Baykal T, Marinho RT, Poordad F, Bourlière M, Sulkowski MS, Wedemeyer H, Tam E, Desmond P, Jensen DM, Di Bisceglie AM, Varunok P, Hassanein T, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Retreatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1604–14. https://​doi.​org/​10.​1056/​NEJMoa1401561.CrossRefPubMed

go back to reference Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13. https://doi.org/10.7326/M15-0785.CrossRefPubMed Zeuzem S, Ghalib R, Reddy KR, Pockros PJ, Ben Ari Z, Zhao Y, Brown DD, Wan S, DiNubile MJ, Nguyen BY, Robertson MN, Wahl J, Barr E, Butterton JR. Grazoprevir-elbasvir combination therapy for treatment-naive cirrhotic and noncirrhotic patients with chronic hepatitis C virus genotype 1, 4, or 6 infection: a randomized trial. Ann Intern Med. 2015;163:1–13. https://​doi.​org/​10.​7326/​M15-0785.CrossRefPubMed

go back to reference Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment- experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis. Virology. 2013;443:278–84. https://doi.org/10.1016/j.virol.2013.05.013.CrossRefPubMed Barnard RJ, McHale CM, Newhard W, Cheney CA, Graham DJ, Himmelberger AL, Strizki J, Hwang PM, Rivera AA, Reeves JD, Nickle D, Dinubile MJ, Hazuda DJ, Mobashery N. Emergence of resistance-associated variants after failed triple therapy with vaniprevir in treatment- experienced non-cirrhotic patients with hepatitis C-genotype 1 infection: a population and clonal analysis. Virology. 2013;443:278–84. https://​doi.​org/​10.​1016/​j.​virol.​2013.​05.​013.CrossRefPubMed

go back to reference Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antivir Res. 2013;99:214–20. https://doi.org/10.1016/j.antiviral.2013.05.015.CrossRefPubMed Lawitz E, Sulkowski M, Jacobson I, Kraft WK, Maliakkal B, Al-Ibrahim M, Gordon SC, Kwo P, Rockstroh JK, Panorchan P, Miller M, Caro L, Barnard R, Hwang PM, Gress J, Quirk E, Mobashery N. Characterization of vaniprevir, a hepatitis C virus NS3/4A protease inhibitor, in patients with HCV genotype 1 infection: safety, antiviral activity, resistance, and pharmacokinetics. Antivir Res. 2013;99:214–20. https://​doi.​org/​10.​1016/​j.​antiviral.​2013.​05.​015.CrossRefPubMed

go back to reference Poordad F. High efficacy of ABT-493 and ABT-530 in HCV genotype- 1 infected patients who have failed direct-acting antiviral-containing regimens: the MAGELLAN-I study [Abstract SAT-157]. In: The International Liver CongressTM EASL—European Association for the Study of the Liver. Barcelona, Spain. Journal of Hepatology; 2016. p. S768. Poordad F. High efficacy of ABT-493 and ABT-530 in HCV genotype- 1 infected patients who have failed direct-acting antiviral-containing regimens: the MAGELLAN-I study [Abstract SAT-157]. In: The International Liver CongressTM EASL—European Association for the Study of the Liver. Barcelona, Spain. Journal of Hepatology; 2016. p. S768.

go back to reference Ng T. Analysis of HCV Genotype 2 and 3 variants in patients treated with combination therapy of next generation HCV direct-acting antiviral agents ABT-493 and ABT-530 [Abstract THU-240]. In: The International liver congress TMEASL—European Association for the Study of the Liver. Barcelona. Journal of Hepatology; 2016. p. S409. Ng T. Analysis of HCV Genotype 2 and 3 variants in patients treated with combination therapy of next generation HCV direct-acting antiviral agents ABT-493 and ABT-530 [Abstract THU-240]. In: The International liver congress TMEASL—European Association for the Study of the Liver. Barcelona. Journal of Hepatology; 2016. p. S409.

go back to reference Lawitz E, Yang JC, Stamm LM, Taylor JG, Cheng G, Brainard DM, Miller MD, Mo H, Dvory-Sobol H. Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor. Antivir Ther. 2017. https://doi.org/10.3851/IMP3202.CrossRef Lawitz E, Yang JC, Stamm LM, Taylor JG, Cheng G, Brainard DM, Miller MD, Mo H, Dvory-Sobol H. Characterization of HCV resistance from a 3-day monotherapy study of voxilaprevir, a novel pangenotypic NS3/4A protease inhibitor. Antivir Ther. 2017. https://​doi.​org/​10.​3851/​IMP3202.CrossRef

go back to reference Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA. Daclatasvir plus peginterferon and ribavirin is non-inferior to peginterferon and ribavirin alone, and reduces duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 2015;148:355–66.e1. https://doi.org/10.1053/j.gastro.2014.10.007.CrossRefPubMed Dore GJ, Lawitz E, Hézode C, Shafran SD, Ramji A, Tatum HA, Taliani G, Tran A, Brunetto MR, Zaltron S, Strasser SI, Weis N, Ghesquiere W, Lee SS, Larrey D, Pol S, Harley H, George J, Fung SK, de Lédinghen V, Hagens P, McPhee F, Hernandez D, Cohen D, Cooney E, Noviello S, Hughes EA. Daclatasvir plus peginterferon and ribavirin is non-inferior to peginterferon and ribavirin alone, and reduces duration of treatment for HCV genotype 2 or 3 infection. Gastroenterology 2015;148:355–66.e1. https://​doi.​org/​10.​1053/​j.​gastro.​2014.​10.​007.CrossRefPubMed

go back to reference Jensen D, Sherman KE, Hézode C, Pol S, Zeuzem S, de Ledinghen V, Tran A, Elkhashab M, Younes ZH, Kugelmas M, Mauss S, Everson G, Luketic V, Vierling J, Serfaty L, Brunetto M, Heo J, Bernstein D, McPhee F, Hennicken D, Mendez P, Hughes E, Noviello S, HALLMARK-QUAD Study Team. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015;63:30–7. https://doi.org/10.1016/j.jhep.2015.02.018.CrossRefPubMed Jensen D, Sherman KE, Hézode C, Pol S, Zeuzem S, de Ledinghen V, Tran A, Elkhashab M, Younes ZH, Kugelmas M, Mauss S, Everson G, Luketic V, Vierling J, Serfaty L, Brunetto M, Heo J, Bernstein D, McPhee F, Hennicken D, Mendez P, Hughes E, Noviello S, HALLMARK-QUAD Study Team. Daclatasvir and asunaprevir plus peginterferon alfa and ribavirin in HCV genotype 1 or 4 non-responders. J Hepatol. 2015;63:30–7. https://​doi.​org/​10.​1016/​j.​jhep.​2015.​02.​018.CrossRefPubMed

go back to reference Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA. ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–35. https://doi.org/10.1002/hep.27726.CrossRefPubMedPubMedCentral Nelson DR, Cooper JN, Lalezari JP, Lawitz E, Pockros PJ, Gitlin N, Freilich BF, Younes ZH, Harlan W, Ghalib R, Oguchi G, Thuluvath PJ, Ortiz-Lasanta G, Rabinovitz M, Bernstein D, Bennett M, Hawkins T, Ravendhran N, Sheikh AM, Varunok P, Kowdley KV, Hennicken D, McPhee F, Rana K, Hughes EA. ALLY-3 Study Team. All-oral 12-week treatment with daclatasvir plus sofosbuvir in patients with hepatitis C virus genotype 3 infection: ALLY-3 phase III study. Hepatology. 2015;61:1127–35. https://​doi.​org/​10.​1002/​hep.​27726.CrossRefPubMedPubMedCentral

go back to reference Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol. 2012;57:24–31. https://doi.org/10.1016/j.jhep.2011.12.029.CrossRefPubMed Lawitz EJ, Gruener D, Hill JM, Marbury T, Moorehead L, Mathias A, Cheng G, Link JO, Wong KA, Mo H, McHutchison JG, Brainard DM. A phase 1, randomized, placebo-controlled, 3-day, dose-ranging study of GS-5885, an NS5A inhibitor, in patients with genotype 1 hepatitis C. J Hepatol. 2012;57:24–31. https://​doi.​org/​10.​1016/​j.​jhep.​2011.​12.​029.CrossRefPubMed

go back to reference Afdhal NH, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98. https://doi.org/10.1056/NEJMoa1402454.CrossRefPubMed Afdhal NH, Zeuzem S, Kwo P, Chojkier M, Gitlin N, Puoti M, Romero-Gomez M, Zarski JP, Agarwal K, Buggisch P, Foster GR, Bräu N, Buti M, Jacobson IM, Subramanian GM, Ding X, Mo H, Yang JC, Pang PS, Symonds WT, McHutchison JG, Muir AJ, Mangia A, Marcellin P, ION-1 Investigators. Ledipasvir and sofosbuvir for untreated HCV genotype 1 infection. N Engl J Med. 2014;370:1889–98. https://​doi.​org/​10.​1056/​NEJMoa1402454.CrossRefPubMed

go back to reference Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59:979–87. https://doi.org/10.1128/AAC.04226-14.CrossRefPubMedPubMedCentral Krishnan P, Beyer J, Mistry N, Koev G, Reisch T, DeGoey D, Kati W, Campbell A, Williams L, Xie W, Setze C, Molla A, Collins C, Pilot-Matias T. In vitro and in vivo antiviral activity and resistance profile of ombitasvir, an inhibitor of hepatitis C virus NS5A. Antimicrob Agents Chemother. 2015;59:979–87. https://​doi.​org/​10.​1128/​AAC.​04226-14.CrossRefPubMedPubMedCentral

go back to reference Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DiNubile MJ, Howe AY. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother. 2015;59:6922–29. https://doi.org/10.1128/AAC.01390-15.CrossRef Liu R, Curry S, McMonagle P, Yeh WW, Ludmerer SW, Jumes PA, Marshall WL, Kong S, Ingravallo P, Black S, Pak I, DiNubile MJ, Howe AY. Susceptibilities of genotype 1a, 1b, and 3 hepatitis C virus variants to the NS5A inhibitor elbasvir. Antimicrob Agents Chemother. 2015;59:6922–29. https://​doi.​org/​10.​1128/​AAC.​01390-15.CrossRef

go back to reference Lawitz EJ, Dvory-Sobol H, Doehle BP, Worth AS, McNally J, Brainard DM, Link JO, Miller M, Mo H. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother. 2016;60:5368–78. https://doi.org/10.1128/AAC.00763-16.CrossRef Lawitz EJ, Dvory-Sobol H, Doehle BP, Worth AS, McNally J, Brainard DM, Link JO, Miller M, Mo H. Clinical resistance to velpatasvir (GS-5816), a novel pan-genotypic inhibitor of the hepatitis C virus NS5A protein. Antimicrob Agents Chemother. 2016;60:5368–78. https://​doi.​org/​10.​1128/​AAC.​00763-16.CrossRef

go back to reference Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S, ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–607. https://doi.org/10.1056/NEJMoa1512610.CrossRefPubMed Feld JJ, Jacobson IM, Hézode C, Asselah T, Ruane PJ, Gruener N, Abergel A, Mangia A, Lai CL, Chan HL, Mazzotta F, Moreno C, Yoshida E, Shafran SD, Towner WJ, Tran TT, McNally J, Osinusi A, Svarovskaia E, Zhu Y, Brainard DM, McHutchison JG, Agarwal K, Zeuzem S, ASTRAL-1 Investigators. Sofosbuvir and velpatasvir for HCV genotype 1, 2, 4, 5, and 6 infection. N Engl J Med. 2015;373:2599–607. https://​doi.​org/​10.​1056/​NEJMoa1512610.CrossRefPubMed

go back to reference Poordad F, Landis CS, Asatryan A, Jackson DF 3rd, Ng TI, Fu B, Lin CW, Yao B, Kort J. High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int. 2016;36:1125–32. https://doi.org/10.1111/liv.13067.CrossRefPubMedPubMedCentral Poordad F, Landis CS, Asatryan A, Jackson DF 3rd, Ng TI, Fu B, Lin CW, Yao B, Kort J. High antiviral activity of NS5A inhibitor ABT-530 with paritaprevir/ritonavir and ribavirin against hepatitis C virus genotype 3 infection. Liver Int. 2016;36:1125–32. https://​doi.​org/​10.​1111/​liv.​13067.CrossRefPubMedPubMedCentral

go back to reference Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M, Culp A, Goljer I, Spreen W. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. Antimicrob Agents Chemother. 2013;57:5037–44. https://doi.org/10.1128/AAC.00910-13.CrossRefPubMedPubMedCentral Wilfret DA, Walker J, Adkison KK, Jones LA, Lou Y, Gan J, Castellino S, Moseley CL, Horton J, de Serres M, Culp A, Goljer I, Spreen W. Safety, tolerability, pharmacokinetics, and antiviral activity of GSK2336805, an inhibitor of hepatitis C virus (HCV) NS5A, in healthy subjects and subjects chronically infected with HCV genotype 1. Antimicrob Agents Chemother. 2013;57:5037–44. https://​doi.​org/​10.​1128/​AAC.​00910-13.CrossRefPubMedPubMedCentral

go back to reference Muir A, Hill J. ACH-3102 A, Second Generation NS5A, Inhibitor, Demonstrates potent antiviral activity in patients with genotype 1A HCV infection despite the presence of baseline NS5A-resistant variants [Abstract 876]. In: The international liver congress TMEASL—European association for the study of the liver; 2013. The Netherlands, Amsterdam: J Hepatol; 2013. p. S360. Muir A, Hill J. ACH-3102 A, Second Generation NS5A, Inhibitor, Demonstrates potent antiviral activity in patients with genotype 1A HCV infection despite the presence of baseline NS5A-resistant variants [Abstract 876]. In: The international liver congress TMEASL—European association for the study of the liver; 2013. The Netherlands, Amsterdam: J Hepatol; 2013. p. S360.

go back to reference Heinrich B. Persistence of resistance-associated variants in hepatitis C virus (HCV) genotypes 1–4 infected subjects following 3-day samatasvir monotherapy. In: International workshop on antiviral drug resistance—meeting the global: antiviral therapy; 2014. Heinrich B. Persistence of resistance-associated variants in hepatitis C virus (HCV) genotypes 1–4 infected subjects following 3-day samatasvir monotherapy. In: International workshop on antiviral drug resistance—meeting the global: antiviral therapy; 2014.

go back to reference Gane EJ. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.CrossRef Gane EJ. Nucleotide polymerase inhibitor sofosbuvir plus ribavirin for hepatitis C. N Engl J Med. 2013;368:34–44.CrossRef

go back to reference Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. L159F and V321A sofosbuvir-associated hepatitis C Virus NS5B substitutions. J Infect Dis. 2016;213:1240-7. https://doi.org/10.1093/infdis/jiv564.CrossRefPubMed Svarovskaia ES, Gane E, Dvory-Sobol H, Martin R, Doehle B, Hedskog C, Jacobson IM, Nelson DR, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. L159F and V321A sofosbuvir-associated hepatitis C Virus NS5B substitutions. J Infect Dis. 2016;213:1240-7. https://​doi.​org/​10.​1093/​infdis/​jiv564.CrossRefPubMed

go back to reference Donaldson EF, Harrington PR, O’Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2014;61:56–65 Donaldson EF, Harrington PR, O’Rear JJ, Naeger LK. Clinical evidence and bioinformatics characterization of potential hepatitis C virus resistance pathways for sofosbuvir. Hepatology. 2014;61:56–65

go back to reference Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603. https://doi.org/10.1056/NEJMoa1315722.CrossRefPubMed Feld JJ, Kowdley KV, Coakley E, Sigal S, Nelson DR, Crawford D, Weiland O, Aguilar H, Xiong J, Pilot-Matias T, DaSilva-Tillmann B, Larsen L, Podsadecki T, Bernstein B. Treatment of HCV with ABT-450/r-ombitasvir and dasabuvir with ribavirin. N Engl J Med. 2014;370:1594–603. https://​doi.​org/​10.​1056/​NEJMoa1315722.CrossRefPubMed

go back to reference Leroy V, Angus P, Bronowicki JP, Hezode C, Pianko S, Pol S, Stuart K, Tse E, McPhee F, Bhore R, Jimenez-Exposito MJ, Thompson AJ. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63:1430–41. https://doi.org/10.1002/hep.28473.CrossRefPubMedPubMedCentral Leroy V, Angus P, Bronowicki JP, Hezode C, Pianko S, Pol S, Stuart K, Tse E, McPhee F, Bhore R, Jimenez-Exposito MJ, Thompson AJ. Daclatasvir, sofosbuvir, and ribavirin for hepatitis C virus genotype 3 and advanced liver disease: a randomized phase III study (ALLY-3+). Hepatology. 2016;63:1430–41. https://​doi.​org/​10.​1002/​hep.​28473.CrossRefPubMedPubMedCentral

go back to reference Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T, Pilot-Matias T, Collins C. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59:5445–54. https://doi.org/10.1128/AAC.00998-15.CrossRefPubMedPubMedCentral Krishnan P, Tripathi R, Schnell G, Reisch T, Beyer J, Irvin M, Xie W, Larsen L, Cohen D, Podsadecki T, Pilot-Matias T, Collins C. Resistance analysis of baseline and treatment-emergent variants in hepatitis C virus genotype 1 in the AVIATOR study with paritaprevir-ritonavir, ombitasvir, and dasabuvir. Antimicrob Agents Chemother. 2015;59:5445–54. https://​doi.​org/​10.​1128/​AAC.​00998-15.CrossRefPubMedPubMedCentral

go back to reference Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, Schiff E, Davis M, Ruane P, Younes Z, Kalmeijer R, Sinha R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J. Witek J.Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3. Randomized study. Hepatology. 2016;64:370–80. https://doi.org/10.1002/hep.28467.CrossRefPubMedPubMedCentral Kwo P, Gitlin N, Nahass R, Bernstein D, Etzkorn K, Rojter S, Schiff E, Davis M, Ruane P, Younes Z, Kalmeijer R, Sinha R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J. Witek J.Simeprevir plus sofosbuvir (12 and 8 weeks) in HCV genotype 1-infected patients without cirrhosis: OPTIMIST-1, a phase 3. Randomized study. Hepatology. 2016;64:370–80. https://​doi.​org/​10.​1002/​hep.​28467.CrossRefPubMedPubMedCentral

go back to reference Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleynard G, Sheikh A, Tobias H, Kugelmas M, Kalmeijer R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Sinha R, Witek J. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2015;64:360–9. https://doi.org/10.1002/hep.28422.CrossRef Lawitz E, Matusow G, DeJesus E, Yoshida EM, Felizarta F, Ghalib R, Godofsky E, Herring RW, Poleynard G, Sheikh A, Tobias H, Kugelmas M, Kalmeijer R, Peeters M, Lenz O, Fevery B, De La Rosa G, Scott J, Sinha R, Witek J. Simeprevir plus sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection and cirrhosis: a phase 3 study (OPTIMIST-2). Hepatology. 2015;64:360–9. https://​doi.​org/​10.​1002/​hep.​28422.CrossRef

go back to reference Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–505. https://doi.org/10.1002/hep.28446.CrossRefPubMedPubMedCentral Poordad F, Schiff ER, Vierling JM, Landis C, Fontana RJ, Yang R, McPhee F, Hughes EA, Noviello S, Swenson ES. Daclatasvir with sofosbuvir and ribavirin for hepatitis C virus infection with advanced cirrhosis or post-liver transplantation recurrence. Hepatology. 2016;63:1493–505. https://​doi.​org/​10.​1002/​hep.​28446.CrossRefPubMedPubMedCentral

go back to reference Pawlotsky JM. Hepatitis C Virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86.CrossRef Pawlotsky JM. Hepatitis C Virus resistance to direct-acting antiviral drugs in interferon-free regimens. Gastroenterology. 2016;151:70–86.CrossRef

go back to reference Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Adinolfi LE, Claar E, Precone D, Stornaiuolo G, Stanzione M, Ascione T, Caroprese M, Zampino R, Parrilli G, Gentile I, Brancaccio G, Iovinella V, Martini S, Masarone M, Fontanella L, Masiello A, Sagnelli E, Punzi R, Salomone Megna A, Santoro R, Gaeta GB, Coppola N. Virological patterns of HCV patients with failure to interferon-free regimens. J Med Virol. 2018. https://doi.org/10.1002/jmv.25022.CrossRefPubMed Starace M, Minichini C, De Pascalis S, Macera M, Occhiello L, Messina V, Sangiovanni V, Adinolfi LE, Claar E, Precone D, Stornaiuolo G, Stanzione M, Ascione T, Caroprese M, Zampino R, Parrilli G, Gentile I, Brancaccio G, Iovinella V, Martini S, Masarone M, Fontanella L, Masiello A, Sagnelli E, Punzi R, Salomone Megna A, Santoro R, Gaeta GB, Coppola N. Virological patterns of HCV patients with failure to interferon-free regimens. J Med Virol. 2018. https://​doi.​org/​10.​1002/​jmv.​25022.CrossRefPubMed

go back to reference Coppola N, Minichini C, Starace M, Sagnelli C, Sagnelli E. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. J Med Virol. 2016;88:1659–71. https://doi.org/10.1002/jmv.24527.CrossRefPubMed Coppola N, Minichini C, Starace M, Sagnelli C, Sagnelli E. Clinical impact of the hepatitis C virus mutations in the era of directly acting antivirals. J Med Virol. 2016;88:1659–71. https://​doi.​org/​10.​1002/​jmv.​24527.CrossRefPubMed

go back to reference Loreta LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: interim evaluations from the PITER network. PLoS One. 2017;12:e0185728. https://doi.org/10.1371/journal.pone.0185728.CrossRef Loreta LA, Gaeta GB, Brunetto MR, Di Leo A, Iannone A, Santantonio TA, Giammario A, Raimondo G, Filomia R, Coppola C, Amoruso DC, Blanc P, Del Pin B, Chemello L, Cavalletto L, Morisco F, Donnarumma L, Rumi MG, Gasbarrini A, Siciliano M, Massari M, Corsini R, Coco B, Madonia S, Cannizzaro M, Zignego AL, Monti M, Russo FP, Zanetto A, Persico M, Masarone M, Villa E, Bernabucci V, Taliani G, Biliotti E, Chessa L, Pasetto MC, Andreone P, Margotti M, Brancaccio G, Ieluzzi D, Borgia G, Zappulo E, Calvaruso V, Petta S, Falzano L, Quaranta MG, Weimer LE, Rosato S, Vella S, Giannini EG. Incidence of DAA failure and the clinical impact of retreatment in real-life patients treated in the advanced stage of liver disease: interim evaluations from the PITER network. PLoS One. 2017;12:e0185728. https://​doi.​org/​10.​1371/​journal.​pone.​0185728.CrossRef

go back to reference Yoshimi S, Imamura M, Murakami E, Hiraga N, Tsuge M, Kawakami Y, Aikata H, Abe H, Hayes CN, Sasaki T, Ochi H, Chayama K. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015;87:1913–20. https://doi.org/10.1002/jmv.24255.CrossRefPubMed Yoshimi S, Imamura M, Murakami E, Hiraga N, Tsuge M, Kawakami Y, Aikata H, Abe H, Hayes CN, Sasaki T, Ochi H, Chayama K. Long term persistence of NS5A inhibitor-resistant hepatitis C virus in patients who failed daclatasvir and asunaprevir therapy. J Med Virol. 2015;87:1913–20. https://​doi.​org/​10.​1002/​jmv.​24255.CrossRefPubMed

go back to reference Lawitz E, Flamm S, Yang JC, Shyam K, Pfeiffer RM. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir- based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol. 2015;62:S192.CrossRef Lawitz E, Flamm S, Yang JC, Shyam K, Pfeiffer RM. Retreatment of patients who failed 8 or 12 weeks of ledipasvir/sofosbuvir- based regimens with ledipasvir/sofosbuvir for 24 weeks. J Hepatol. 2015;62:S192.CrossRef

go back to reference Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman C, Davis MN, Hinestrosa F. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A- containing DAA regimens: results of the retreatment study. J Hepatol. 2016;64:147.CrossRef Gane EJ, Shiffman ML, Etzkorn K, Morelli G, Stedman C, Davis MN, Hinestrosa F. Sofosbuvir/velpatasvir in combination with ribavirin for 24 weeks is effective retreatment for patients who failed prior NS5A- containing DAA regimens: results of the retreatment study. J Hepatol. 2016;64:147.CrossRef

go back to reference Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM, Ma J, Ding X, Afdhal NH, Kowdley KV, Gane EJ, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. Prevalence of resistance- associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151:501–12. https://doi.org/10.1053/j.gastro.2016.06.002.CrossRefPubMed Sarrazin C, Dvory-Sobol H, Svarovskaia ES, Doehle BP, Pang PS, Chuang SM, Ma J, Ding X, Afdhal NH, Kowdley KV, Gane EJ, Lawitz E, Brainard DM, McHutchison JG, Miller MD, Mo H. Prevalence of resistance- associated substitutions in HCV NS5A, NS5B, or NS3 and outcomes of treatment with ledipasvir and sofosbuvir. Gastroenterology. 2016;151:501–12. https://​doi.​org/​10.​1053/​j.​gastro.​2016.​06.​002.CrossRefPubMed

go back to reference Craxi A, Perno CF, Vigano M, Ceccherini-Silberstein F, Petta S. From current status to optimization of HCV treatment: recommendations from an expert panel. Dig Liver Dis. 2016;48:995–1005.CrossRef Craxi A, Perno CF, Vigano M, Ceccherini-Silberstein F, Petta S. From current status to optimization of HCV treatment: recommendations from an expert panel. Dig Liver Dis. 2016;48:995–1005.CrossRef

go back to reference Hézode C, Chevaliez S, Scoazec G, Soulier A, Varaut A, Bouvier-Alias M, Ruiz I, Roudot-Thoraval F, Mallat A, Féray C, Pawlotsky JM. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology. 2016;63:1809–16. https://doi.org/10.1002/hep.28491.CrossRefPubMed Hézode C, Chevaliez S, Scoazec G, Soulier A, Varaut A, Bouvier-Alias M, Ruiz I, Roudot-Thoraval F, Mallat A, Féray C, Pawlotsky JM. Retreatment with sofosbuvir and simeprevir of patients with hepatitis C virus genotype 1 or 4 who previously failed a daclatasvir-containing regimen. Hepatology. 2016;63:1809–16. https://​doi.​org/​10.​1002/​hep.​28491.CrossRefPubMed

go back to reference Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Rabinovitz M, Towner WJ, Gane EJ, Stedman CA, Reddy KR, Roberts SK. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163:809–17. https://doi.org/10.7326/M15-1014.CrossRefPubMed Pianko S, Flamm SL, Shiffman ML, Kumar S, Strasser SI, Dore GJ, McNally J, Brainard DM, Han L, Doehle B, Mogalian E, McHutchison JG, Rabinovitz M, Towner WJ, Gane EJ, Stedman CA, Reddy KR, Roberts SK. Sofosbuvir plus velpatasvir combination therapy for treatment-experienced patients with genotype 1 or 3 hepatitis C virus infection: a randomized trial. Ann Intern Med. 2015;163:809–17. https://​doi.​org/​10.​7326/​M15-1014.CrossRefPubMed

go back to reference Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62:79–86. https://doi.org/10.1002/hep.27826.CrossRefPubMed Reddy KR, Bourlière M, Sulkowski M, Omata M, Zeuzem S, Feld JJ, Lawitz E, Marcellin P, Welzel TM, Hyland R, Ding X, Yang J, Knox S, Pang P, Dvory-Sobol H, Subramanian GM, Symonds W, McHutchison JG, Mangia A, Gane E, Mizokami M, Pol S, Afdhal N. Ledipasvir and sofosbuvir in patients with genotype 1 hepatitis C virus infection and compensated cirrhosis: an integrated safety and efficacy analysis. Hepatology. 2015;62:79–86. https://​doi.​org/​10.​1002/​hep.​27826.CrossRefPubMed

go back to reference Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S, POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134–46. https://doi.org/10.1056/NEJMoa1613512.CrossRefPubMed Bourliere M, Gordon SC, Flamm SL, Cooper CL, Ramji A, Tong M, Ravendhran N, Vierling JM, Tran TT, Pianko S, Bansal MB, de Lédinghen V, Hyland RH, Stamm LM, Dvory-Sobol H, Svarovskaia E, Zhang J, Huang KC, Subramanian GM, Brainard DM, McHutchison JG, Verna EC, Buggisch P, Landis CS, Younes ZH, Curry MP, Strasser SI, Schiff ER, Reddy KR, Manns MP, Kowdley KV, Zeuzem S, POLARIS-1 and POLARIS-4 Investigators. Sofosbuvir, velpatasvir, and voxilaprevir for previously treated HCV infection. N Engl J Med. 2017;376:2134–46. https://​doi.​org/​10.​1056/​NEJMoa1613512.CrossRefPubMed

go back to reference Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2017. https://doi.org/10.1002/hep.29671.CrossRefPubMedPubMedCentral Poordad F, Pol S, Asatryan A, Buti M, Shaw D, Hézode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ. Glecaprevir/pibrentasvir in patients with hepatitis C virus genotype 1 or 4 and past direct-acting antiviral treatment failure. Hepatology. 2017. https://​doi.​org/​10.​1002/​hep.​29671.CrossRefPubMedPubMedCentral

go back to reference Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389–97. https://doi.org/10.1002/hep.29081.CrossRefPubMedPubMedCentral Poordad F, Felizarta F, Asatryan A, Sulkowski MS, Reindollar RW, Landis CS, Landis CS, Gordon SC, Flamm SL, Fried MW, Bernstein DE, Lin CW, Liu R, Lovell SS, Ng TI, Kort J, Mensa FJ. Glecaprevir and pibrentasvir for 12 weeks for hepatitis C virus genotype 1 infection and prior direct-acting antiviral treatment. Hepatology. 2017;66:389–97. https://​doi.​org/​10.​1002/​hep.​29081.CrossRefPubMedPubMedCentral

go back to reference Poordad F, Pol S, Asatryan A, Buti M, Shaw DR, Hezode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ. Glecapreir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Gastroenterology. 2017;152:1057. https://doi.org/10.1002/hep.29671.CrossRef Poordad F, Pol S, Asatryan A, Buti M, Shaw DR, Hezode C, Felizarta F, Reindollar RW, Gordon SC, Pianko S, Fried MW, Bernstein DE, Gallant J, Lin CW, Lei Y, Ng TI, Krishnan P, Kopecky-Bromberg S, Kort J, Mensa FJ. Glecapreir and pibrentasvir for 12 or 16 weeks in patients with chronic HCV genotype 1 or 4 and prior direct-acting antiviral treatment failure. Gastroenterology. 2017;152:1057. https://​doi.​org/​10.​1002/​hep.​29671.CrossRef

go back to reference de Lédinghen V, Laforest C, Hézode C, Pol S, Renault A, Alric L, Larrey D, Métivier S, Tran A, Jézéquel C, Samuel D, Zoulim F, Tual C, Pailhé A, Gibowski S, Bourlière M, Bellissant E, Pawlotsky JM. Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE. Clin Infect Dis. 2017. https://doi.org/10.1093/cid/cix916.CrossRef de Lédinghen V, Laforest C, Hézode C, Pol S, Renault A, Alric L, Larrey D, Métivier S, Tran A, Jézéquel C, Samuel D, Zoulim F, Tual C, Pailhé A, Gibowski S, Bourlière M, Bellissant E, Pawlotsky JM. Retreatment with sofosbuvir plus grazoprevir/elbasvir plus ribavirin of patients with hepatitis C virus genotype 1 or 4 who previously failed a NS5A or NS3-containing regimen. ANRS HC34 REVENGE. Clin Infect Dis. 2017. https://​doi.​org/​10.​1093/​cid/​cix916.CrossRef

go back to reference Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F, HCV Italian Resistance Network Study Group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37:514–28. https://doi.org/10.1111/liv.13327.CrossRefPubMed Di Maio VC, Cento V, Lenci I, Aragri M, Rossi P, Barbaliscia S, Melis M, Verucchi G, Magni CF, Teti E, Bertoli A, Antonucci F, Bellocchi MC, Micheli V, Masetti C, Landonio S, Francioso S, Santopaolo F, Pellicelli AM, Calvaruso V, Gianserra L, Siciliano M, Romagnoli D, Cozzolongo R, Grieco A, Vecchiet J, Morisco F, Merli M, Brancaccio G, Di Biagio A, Loggi E, Mastroianni CM, Pace Palitti V, Tarquini P, Puoti M, Taliani G, Sarmati L, Picciotto A, Vullo V, Caporaso N, Paoloni M, Pasquazzi C, Rizzardini G, Parruti G, Craxì A, Babudieri S, Andreoni M, Angelico M, Perno CF, Ceccherini-Silberstein F, HCV Italian Resistance Network Study Group. Multiclass HCV resistance to direct-acting antiviral failure in real-life patients advocates for tailored second-line therapies. Liver Int. 2017;37:514–28. https://​doi.​org/​10.​1111/​liv.​13327.CrossRefPubMed

go back to reference Salerno F, Borzio M, Pedicino C, Simonetti R, Rossini A, Boccia S, Cacciola I, Burroughs AK, Manini MA, La Mura V, Angeli P, Bernardi M, Dalla Gasperina D, Dionigi E, Dibenedetto C, Arghittu M, AISF Investigators. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int. 2017;37:71–9. https://doi.org/10.1111/liv.13195.CrossRefPubMed Salerno F, Borzio M, Pedicino C, Simonetti R, Rossini A, Boccia S, Cacciola I, Burroughs AK, Manini MA, La Mura V, Angeli P, Bernardi M, Dalla Gasperina D, Dionigi E, Dibenedetto C, Arghittu M, AISF Investigators. The impact of infection by multidrug-resistant agents in patients with cirrhosis. A multicenter prospective study. Liver Int. 2017;37:71–9. https://​doi.​org/​10.​1111/​liv.​13195.CrossRefPubMed

go back to reference Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597–605.CrossRef Manns M, Pol S, Jacobson IM, Marcellin P, Gordon SC, Peng CY, Chang TT, Everson GT, Heo J, Gerken G, Yoffe B, Towner WJ, Bourliere M, Metivier S, Chu CJ, Sievert W, Bronowicki JP, Thabut D, Lee YJ, Kao JH, McPhee F, Kopit J, Mendez P, Linaberry M, Hughes E, Noviello S, HALLMARK-DUAL Study Team. All-oral daclatasvir plus asunaprevir for hepatitis C virus genotype 1b: a multinational, phase 3, multicohort study. Lancet. 2014;384:1597–605.CrossRef

go back to reference Kumad H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91. https://doi.org/10.1002/hep.27113.CrossRef Kumad H, Suzuki Y, Ikeda K, Toyota J, Karino Y, Chayama K, Kawakami Y, Ido A, Yamamoto K, Takaguchi K, Izumi N, Koike K, Takehara T, Kawada N, Sata M, Miyagoshi H, Eley T, McPhee F, Damokosh A, Ishikawa H, Hughes E. Daclatasvir plus asunaprevir for chronic HCV genotype 1b infection. Hepatology. 2014;59:2083–91. https://​doi.​org/​10.​1002/​hep.​27113.CrossRef

go back to reference Fevery B, Thys K, Van Eygen V, Verbinnen T, Van Rossem E, Buelens A, Aerssens J, Witek J, Picchio G, De Meyer S, Lenz O. Pre-existence and persistence of resistant minority hepatitis C virus variants in genotype 1-infected patients treated with simeprevir/peginterferon/ribavirin. Open Forum Infect Dis. 2016;3:ofw052. https://doi.org/10.1093/ofid/ofw052.CrossRefPubMedPubMedCentral Fevery B, Thys K, Van Eygen V, Verbinnen T, Van Rossem E, Buelens A, Aerssens J, Witek J, Picchio G, De Meyer S, Lenz O. Pre-existence and persistence of resistant minority hepatitis C virus variants in genotype 1-infected patients treated with simeprevir/peginterferon/ribavirin. Open Forum Infect Dis. 2016;3:ofw052. https://​doi.​org/​10.​1093/​ofid/​ofw052.CrossRefPubMedPubMedCentral

go back to reference Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D, Bartels D, Zhou Y, Nicolas O, Rao BG, Müh U, Hanzelka B, Tigges A, Rijnbrand R, Kieffer TL. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob Agents Chemother. 2013;57:6236–45. https://doi.org/10.1128/AAC.01578-13.CrossRefPubMedPubMedCentral Jiang M, Mani N, Lin C, Ardzinski A, Nelson M, Reagan D, Bartels D, Zhou Y, Nicolas O, Rao BG, Müh U, Hanzelka B, Tigges A, Rijnbrand R, Kieffer TL. In vitro phenotypic characterization of hepatitis C virus NS3 protease variants observed in clinical studies of telaprevir. Antimicrob Agents Chemother. 2013;57:6236–45. https://​doi.​org/​10.​1128/​AAC.​01578-13.CrossRefPubMedPubMedCentral

go back to reference Lagace L, White PW, Bousquet C, Dansereau N, Dô F, Llinas-Brunet M, Marquis M, Massariol MJ, Maurice R, Spickler C, Thibeault D, Triki I, Zhao S, Kukolj G. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother. 2012;56:569–72. https://doi.org/10.1128/AAC.05166-11.CrossRef Lagace L, White PW, Bousquet C, Dansereau N, Dô F, Llinas-Brunet M, Marquis M, Massariol MJ, Maurice R, Spickler C, Thibeault D, Triki I, Zhao S, Kukolj G. In vitro resistance profile of the hepatitis C virus NS3 protease inhibitor BI 201335. Antimicrob Agents Chemother. 2012;56:569–72. https://​doi.​org/​10.​1128/​AAC.​05166-11.CrossRef

go back to reference Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol. 2011;85:7312–20.CrossRef Fridell RA, Qiu D, Valera L, Wang C, Rose RE, Gao M. Distinct functions of NS5A in hepatitis C virus RNA replication uncovered by studies with the NS5A inhibitor BMS-790052. J Virol. 2011;85:7312–20.CrossRef

go back to reference Verbinnen T, Fevery B, Vijgen L, Jacobs T, De Meyer S, Lenz O. In vitro activity of simeprevir against hepatitis C virus genotype 1 clinical isolates and its correlation with NS3 sequence and site-directed mutants. Antimicrob Agents Chemother. 2015;59:7548–57.CrossRef Verbinnen T, Fevery B, Vijgen L, Jacobs T, De Meyer S, Lenz O. In vitro activity of simeprevir against hepatitis C virus genotype 1 clinical isolates and its correlation with NS3 sequence and site-directed mutants. Antimicrob Agents Chemother. 2015;59:7548–57.CrossRef

go back to reference Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–32. https://doi.org/10.1002/hep.27934.CrossRefPubMed Lontok E, Harrington P, Howe A, Kieffer T, Lennerstrand J, Lenz O, McPhee F, Mo H, Parkin N, Pilot-Matias T, Miller V. Hepatitis C virus drug resistance-associated substitutions: state of the art summary. Hepatology. 2015;62:1623–32. https://​doi.​org/​10.​1002/​hep.​27934.CrossRefPubMed

go back to reference Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X, Setze C, Rodrigues L Jr, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir-ritonavir and ombitasvir. Antimicrob Agents Chemother. 2016;60:1106–13. https://doi.org/10.1128/AAC.02606-15.CrossRefPubMedPubMedCentral Krishnan P, Schnell G, Tripathi R, Beyer J, Reisch T, Zhang X, Setze C, Rodrigues L Jr, Burroughs M, Redman R, Chayama K, Kumada H, Collins C, Pilot-Matias T. Analysis of hepatitis C virus genotype 1b resistance variants in Japanese patients treated with paritaprevir-ritonavir and ombitasvir. Antimicrob Agents Chemother. 2016;60:1106–13. https://​doi.​org/​10.​1128/​AAC.​02606-15.CrossRefPubMedPubMedCentral

go back to reference Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, Reisch T, Irvin M, Hopkins T, Pithawalla R, Middleton T, Ng T, McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59:988–97. https://doi.org/10.1128/AAC.04227-14.CrossRefPubMedPubMedCentral Pilot-Matias T, Tripathi R, Cohen D, Gaultier I, Dekhtyar T, Lu L, Reisch T, Irvin M, Hopkins T, Pithawalla R, Middleton T, Ng T, McDaniel K, Or YS, Menon R, Kempf D, Molla A, Collins C. In vitro and in vivo antiviral activity and resistance profile of the hepatitis C virus NS3/4A protease inhibitor ABT-450. Antimicrob Agents Chemother. 2015;59:988–97. https://​doi.​org/​10.​1128/​AAC.​04227-14.CrossRefPubMedPubMedCentral

go back to reference Ludmerer SW, Hirano T, Black S, Howe AY, Chang W, Takase A, Nakamura K, Tanaka Y, Kumada H, Hayashi N, Nickle D. HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials. Antivir Res. 2016;130:118–29. https://doi.org/10.1016/j.antiviral.2016.03.004.CrossRefPubMed Ludmerer SW, Hirano T, Black S, Howe AY, Chang W, Takase A, Nakamura K, Tanaka Y, Kumada H, Hayashi N, Nickle D. HCV evolutionary genetics of SVR versus virologic failure assessed from the vaniprevir phase III registration trials. Antivir Res. 2016;130:118–29. https://​doi.​org/​10.​1016/​j.​antiviral.​2016.​03.​004.CrossRefPubMed

go back to reference Poordad F, Gordon SC, Asatryan A, et al. High efficacy of ABT-493 and ABT-530 in HCV genotype-1 infected patients who have failed direct-acting antiviral-containing regimens: the MAGELLAN-I 19 study [Abstract SAT-157]. In: The international liver congress™ EASL—European association for the study of the liver. Barcelona, Spain: Journal of Hepatology; 2016. p. S768. Poordad F, Gordon SC, Asatryan A, et al. High efficacy of ABT-493 and ABT-530 in HCV genotype-1 infected patients who have failed direct-acting antiviral-containing regimens: the MAGELLAN-I 19 study [Abstract SAT-157]. In: The international liver congress™ EASL—European association for the study of the liver. Barcelona, Spain: Journal of Hepatology; 2016. p. S768.

go back to reference Gane EJ, Schwabe C, Hyland RH, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology. 2016;151:448–456 Gane EJ, Schwabe C, Hyland RH, et al. Efficacy of the combination of sofosbuvir, velpatasvir, and the NS3/4A protease inhibitor GS-9857 in treatment-naive or previously treated patients with HCV genotype 1 or 3 infections. Gastroenterology. 2016;151:448–456

go back to reference Lawitz E, Dvory-Sobol H, Yang JC, et al. Characterization of HCV resistance from a 3-day monotherapy study of GS-9857, a novel pangenotypic NS3/4A protease inhibitor [Abstract 718]. American Association for the Study of Liver Diseases (AASLD), vol. 62 San Francisco: Hepatology; 2015. p. 119A. Lawitz E, Dvory-Sobol H, Yang JC, et al. Characterization of HCV resistance from a 3-day monotherapy study of GS-9857, a novel pangenotypic NS3/4A protease inhibitor [Abstract 718]. American Association for the Study of Liver Diseases (AASLD), vol. 62 San Francisco: Hepatology; 2015. p. 119A.

go back to reference Bartolini B, Selleri M, Garbuglia AR, Giombini E, Taibi C, Lionetti R, D’Offizi G, Capobianchi MR. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir resistant variants in breakthrough patients assessed by UDPS: a case study. J Clin Virol. 2015;72:60–5.CrossRef Bartolini B, Selleri M, Garbuglia AR, Giombini E, Taibi C, Lionetti R, D’Offizi G, Capobianchi MR. HCV NS3 quasispecies in liver and plasma and dynamics of telaprevir resistant variants in breakthrough patients assessed by UDPS: a case study. J Clin Virol. 2015;72:60–5.CrossRef

go back to reference Beloukas A, King S, Childs K, Papadimitropoulos A, Hopkins M, Atkins M, Agarwal K, Nelson M, Geretti AM. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK. Clin Microbiol Infect. 2015;21:1033–339.CrossRef Beloukas A, King S, Childs K, Papadimitropoulos A, Hopkins M, Atkins M, Agarwal K, Nelson M, Geretti AM. Detection of the NS3 Q80K polymorphism by Sanger and deep sequencing in hepatitis C virus genotype 1a strains in the UK. Clin Microbiol Infect. 2015;21:1033–339.CrossRef

go back to reference Boglione L, De Nicolo A, Cardellino CS, Ruggiero T, Ghisetti V, Cariti G, Di Perri G, D’Avolio A. Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. Clin Microbiol Infect. 2015;21:205.e1.CrossRef Boglione L, De Nicolo A, Cardellino CS, Ruggiero T, Ghisetti V, Cariti G, Di Perri G, D’Avolio A. Relationship between the early boceprevir-S isomer plasma concentrations and the onset of breakthrough during HCV genotype 1 triple therapy. Clin Microbiol Infect. 2015;21:205.e1.CrossRef

go back to reference Liverton NJ, Carroll SS, Dimuzio J, et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother. 2010;54:305–11.CrossRef Liverton NJ, Carroll SS, Dimuzio J, et al. MK-7009, a potent and selective inhibitor of hepatitis C virus NS3/4A protease. Antimicrob Agents Chemother. 2010;54:305–11.CrossRef

go back to reference Verbinnen T, Van Marck H, Vandenbroucke I, et al. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol. 2010;84:11124–33.CrossRef Verbinnen T, Van Marck H, Vandenbroucke I, et al. Tracking the evolution of multiple in vitro hepatitis C virus replicon variants under protease inhibitor selection pressure by 454 deep sequencing. J Virol. 2010;84:11124–33.CrossRef

go back to reference Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramiere C, Scholtes C, Ha€ım-Boukobza S, Roque-Afonso AM, Besse B, Andre-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, Velay A, Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P. Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin. J Clin Microbiol. 2015;53:2195–202.CrossRef Larrat S, Vallet S, David-Tchouda S, Caporossi A, Margier J, Ramiere C, Scholtes C, Ha€ım-Boukobza S, Roque-Afonso AM, Besse B, Andre-Garnier E, Mohamed S, Halfon P, Pivert A, LeGuillou-Guillemette H, Abravanel F, Guivarch M, Mackiewicz V, Lada O, Mourez T, Plantier JC, Baazia Y, Alain S, Hantz S, Thibault V, Gaudy-Graffin C, Bouvet D, Mirand A, Henquell C, Gozlan J, Lagathu G, Pronier C, Velay A, Schvoerer E, Trimoulet P, Fleury H, Bouvier-Alias M, Brochot E, Duverlie G, Maylin S, Gouriou S, Pawlotsky JM, Morand P. Naturally occurring resistance-associated variants of hepatitis C virus protease inhibitors in poor responders to pegylated interferon-ribavirin. J Clin Microbiol. 2015;53:2195–202.CrossRef

go back to reference Susser S, Dietz J, Vermehren J, et al. European RAVs database: frequency and characteristics of RAVs in treatment-naive and DAA-experienced patients [Abstract PS007]. In: Abstracts of the international liver congress™ 2016, EASL—European Association for the Study of the Liver. Barcelona, Spain: Journal of Hepatology; 2016. p. S139. Susser S, Dietz J, Vermehren J, et al. European RAVs database: frequency and characteristics of RAVs in treatment-naive and DAA-experienced patients [Abstract PS007]. In: Abstracts of the international liver congress™ 2016, EASL—European Association for the Study of the Liver. Barcelona, Spain: Journal of Hepatology; 2016. p. S139.

go back to reference Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, Setze C, Pilot-Matias T, Patwardhan M, Vilchez RA, Burroughs M, Redman R. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037–46. https://doi.org/10.1002/hep.27972.CrossRefPubMedPubMedCentral Kumada H, Chayama K, Rodrigues L Jr, Suzuki F, Ikeda K, Toyoda H, Sato K, Karino Y, Matsuzaki Y, Kioka K, Setze C, Pilot-Matias T, Patwardhan M, Vilchez RA, Burroughs M, Redman R. Randomized phase 3 trial of ombitasvir/paritaprevir/ritonavir for hepatitis C virus genotype 1b-infected Japanese patients with or without cirrhosis. Hepatology. 2015;62:1037–46. https://​doi.​org/​10.​1002/​hep.​27972.CrossRefPubMedPubMedCentral

go back to reference Schnell G, Tripathi R, Beyer J, et al. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother. 2015;59:6807–15.CrossRef Schnell G, Tripathi R, Beyer J, et al. Hepatitis C virus genotype 4 resistance and subtype demographic characterization of patients treated with ombitasvir plus paritaprevir/ritonavir. Antimicrob Agents Chemother. 2015;59:6807–15.CrossRef

go back to reference Iio E, Shimada N, Abe H, et al. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol. 2016. https://doi.org/10.1007/s00535-016-1225-x (Epub 2016 May 28).CrossRefPubMed Iio E, Shimada N, Abe H, et al. Efficacy of daclatasvir/asunaprevir according to resistance-associated variants in chronic hepatitis C with genotype 1. J Gastroenterol. 2016. https://​doi.​org/​10.​1007/​s00535-016-1225-x (Epub 2016 May 28).CrossRefPubMed

go back to reference McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013;58:902–11. https://doi.org/10.1002/hep.26388 (Epub 2013 Jul 16).CrossRefPubMed McPhee F, Hernandez D, Yu F, et al. Resistance analysis of hepatitis C virus genotype 1 prior treatment null responders receiving daclatasvir and asunaprevir. Hepatology. 2013;58:902–11. https://​doi.​org/​10.​1002/​hep.​26388 (Epub 2013 Jul 16).CrossRefPubMed

go back to reference Lenz O, Verbinnen T, Fevery B, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in phase IIb/III studies. J Hepatol. 2015;62:1008–14.CrossRef Lenz O, Verbinnen T, Fevery B, et al. Virology analyses of HCV isolates from genotype 1-infected patients treated with simeprevir plus peginterferon/ribavirin in phase IIb/III studies. J Hepatol. 2015;62:1008–14.CrossRef

go back to reference Ruggiero T, Proietti A, Boglione L, Milia MG, Allice T, Burdino E, Orofino G, Bonora S, Di Perri G, Ghisetti V. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience. Arch Virol. 2015;160:2881–5.CrossRef Ruggiero T, Proietti A, Boglione L, Milia MG, Allice T, Burdino E, Orofino G, Bonora S, Di Perri G, Ghisetti V. Predominance of hepatitis C virus Q80K among NS3 baseline-resistance associated amino acid variants in direct-antiviral-agent-naïve patients with chronic hepatitis: single-centre experience. Arch Virol. 2015;160:2881–5.CrossRef

go back to reference Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C, European HCV Resistance Study Group. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology. 2017. https://doi.org/10.1053/j.gastro.2017.11.007.CrossRefPubMedPubMedCentral Dietz J, Susser S, Vermehren J, Peiffer KH, Grammatikos G, Berger A, Ferenci P, Buti M, Müllhaupt B, Hunyady B, Hinrichsen H, Mauss S, Petersen J, Buggisch P, Felten G, Hüppe D, Knecht G, Lutz T, Schott E, Berg C, Spengler U, von Hahn T, Berg T, Zeuzem S, Sarrazin C, European HCV Resistance Study Group. Patterns of resistance-associated substitutions in patients with chronic HCV infection following treatment with direct-acting antivirals. Gastroenterology. 2017. https://​doi.​org/​10.​1053/​j.​gastro.​2017.​11.​007.CrossRefPubMedPubMedCentral

go back to reference Taylor JG, Appleby T, Barauskas O, et al. Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 [Abstract P0899]. In: EASL—the international liver congress 2015 50th annual Meeting of the European association for the Study of the Liver. Vienna, Austria: Journal of Hepatology; 2015. p. S681. Taylor JG, Appleby T, Barauskas O, et al. Preclinical profile of the pan-genotypic HCV NS3/4A protease inhibitor GS-9857 [Abstract P0899]. In: EASL—the international liver congress 2015 50th annual Meeting of the European association for the Study of the Liver. Vienna, Austria: Journal of Hepatology; 2015. p. S681.

go back to reference Kattakuzhy S, Wilson E, Sidharthan S, et al. Moderate sustained virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease. Clin Infect Dis. 2016;62:440–7.PubMed Kattakuzhy S, Wilson E, Sidharthan S, et al. Moderate sustained virologic response rates with 6-week combination directly acting anti-hepatitis C virus therapy in patients with advanced liver disease. Clin Infect Dis. 2016;62:440–7.PubMed

go back to reference Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W, Nájera I, Smith P, Zeuzem S, Kossen K, Sarrazin C, Seiwert SD. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother. 2012;56:271–79. https://doi.org/10.1128/AAC.05636-11.CrossRef Lim SR, Qin X, Susser S, Nicholas JB, Lange C, Herrmann E, Hong J, Arfsten A, Hooi L, Bradford W, Nájera I, Smith P, Zeuzem S, Kossen K, Sarrazin C, Seiwert SD. Virologic escape during danoprevir (ITMN-191/RG7227) monotherapy is hepatitis C virus subtype dependent and associated with R155K substitution. Antimicrob Agents Chemother. 2012;56:271–79. https://​doi.​org/​10.​1128/​AAC.​05636-11.CrossRef

go back to reference Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012;8:e1002832. https://doi.org/10.1371/journal.ppat.1002832.CrossRefPubMedPubMedCentral Romano KP, Ali A, Aydin C, Soumana D, Ozen A, Deveau LM, Silver C, Cao H, Newton A, Petropoulos CJ, Huang W, Schiffer CA. The molecular basis of drug resistance against hepatitis C virus NS3/4A protease inhibitors. PLoS Pathog. 2012;8:e1002832. https://​doi.​org/​10.​1371/​journal.​ppat.​1002832.CrossRefPubMedPubMedCentral

go back to reference Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM. Hepatitis C virus genotype 1 to 6 protease inhibitor escape variants: in vitro selection, fitness, and resistance patterns in the context of the infectious viral life cycle. Antimicrob Agents Chemother. 2016;60:3563–78. https://doi.org/10.1128/AAC.02929-15.CrossRefPubMedPubMedCentral Serre SB, Jensen SB, Ghanem L, Humes DG, Ramirez S, Li YP, Krarup H, Bukh J, Gottwein JM. Hepatitis C virus genotype 1 to 6 protease inhibitor escape variants: in vitro selection, fitness, and resistance patterns in the context of the infectious viral life cycle. Antimicrob Agents Chemother. 2016;60:3563–78. https://​doi.​org/​10.​1128/​AAC.​02929-15.CrossRefPubMedPubMedCentral

go back to reference Howe AY, Black S, Curry S, Ludmerer SW, Liu R, Barnard RJ, Newhard W, Hwang PM, Nickle D, Gilbert C, Caro L, DiNubile MJ, Mobashery N. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014;59:1657–65. https://doi.org/10.1093/cid/ciu696.CrossRefPubMed Howe AY, Black S, Curry S, Ludmerer SW, Liu R, Barnard RJ, Newhard W, Hwang PM, Nickle D, Gilbert C, Caro L, DiNubile MJ, Mobashery N. Virologic resistance analysis from a phase 2 study of MK-5172 combined with pegylated interferon/ribavirin in treatment-naive patients with hepatitis C virus genotype 1 infection. Clin Infect Dis. 2014;59:1657–65. https://​doi.​org/​10.​1093/​cid/​ciu696.CrossRefPubMed

go back to reference Soumana DI, Ali A, Schiffer CA. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem Biol. 2014;9:2485–90.CrossRef Soumana DI, Ali A, Schiffer CA. Structural analysis of asunaprevir resistance in HCV NS3/4A protease. ACS Chem Biol. 2014;9:2485–90.CrossRef

go back to reference Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM. Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance. Antimicrob Agents Chemother. 2015;59:7426–36. https://doi.org/10.1128/AAC.01953-15.CrossRefPubMedPubMedCentral Jensen SB, Serre SB, Humes DG, Ramirez S, Li YP, Bukh J, Gottwein JM. Substitutions at NS3 residue 155, 156, or 168 of hepatitis C virus genotypes 2 to 6 induce complex patterns of protease inhibitor resistance. Antimicrob Agents Chemother. 2015;59:7426–36. https://​doi.​org/​10.​1128/​AAC.​01953-15.CrossRefPubMedPubMedCentral

go back to reference Black S, Pak I, Ingravallo P, et al. Resistance analysis of virologic failures in hepatitis c genotype 1-infected patients treated with grazoprevir + elbasvir ± ribavirin: the C-WORTHY study [abstract P0891]. In: The international liver congress 2015, 50th annual meeting of the European association for the Study of the Liver (EASL). Vienna, Austria: Journal of Hepatology; 2015. p. S677–S8. Black S, Pak I, Ingravallo P, et al. Resistance analysis of virologic failures in hepatitis c genotype 1-infected patients treated with grazoprevir + elbasvir ± ribavirin: the C-WORTHY study [abstract P0891]. In: The international liver congress 2015, 50th annual meeting of the European association for the Study of the Liver (EASL). Vienna, Austria: Journal of Hepatology; 2015. p. S677–S8.

go back to reference Ng T, Reisch T, Middleton T, et al. ABT-493, a Potent HCV NS3/4A protease inhibitor with broad genotype coverage [abstract 636]. In: 21st conference on retroviruses and opportunistic infections-CROI. Boston; 2014. Ng T, Reisch T, Middleton T, et al. ABT-493, a Potent HCV NS3/4A protease inhibitor with broad genotype coverage [abstract 636]. In: 21st conference on retroviruses and opportunistic infections-CROI. Boston; 2014.

go back to reference Reau N, Nguyen MH, Kowdley KV, et al. Integrated resistance analyses of HCV-infected patients treated with sofosbuvir, velpatasvir and voxilaprevir for 8 and 12 weeks from phase 2 studies [Poster 846. American Association for the Study of Liver Diseases (AASLD). Boston: Hepatology; 2016. Reau N, Nguyen MH, Kowdley KV, et al. Integrated resistance analyses of HCV-infected patients treated with sofosbuvir, velpatasvir and voxilaprevir for 8 and 12 weeks from phase 2 studies [Poster 846. American Association for the Study of Liver Diseases (AASLD). Boston: Hepatology; 2016.

go back to reference Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol. 2013;8:1469–78. https://doi.org/10.1021/cb400100g.CrossRefPubMedPubMedCentral Ali A, Aydin C, Gildemeister R, Romano KP, Cao H, Ozen A, Soumana D, Newton A, Petropoulos CJ, Huang W, Schiffer CA. Evaluating the role of macrocycles in the susceptibility of hepatitis C virus NS3/4A protease inhibitors to drug resistance. ACS Chem Biol. 2013;8:1469–78. https://​doi.​org/​10.​1021/​cb400100g.CrossRefPubMedPubMedCentral

go back to reference Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655–62. https://doi.org/10.1016/j.jhep.2012.09.037.CrossRefPubMed Suzuki Y, Ikeda K, Suzuki F, Toyota J, Karino Y, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hu W, Eley T, McPhee F, Hughes E, Kumada H. Dual oral therapy with daclatasvir and asunaprevir for patients with HCV genotype 1b infection and limited treatment options. J Hepatol. 2013;58:655–62. https://​doi.​org/​10.​1016/​j.​jhep.​2012.​09.​037.CrossRefPubMed

go back to reference Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354–69. https://doi.org/10.1056/NEJMoa1702417.CrossRefPubMed Zeuzem S, Foster GR, Wang S, Asatryan A, Gane E, Feld JJ, Asselah T, Bourlière M, Ruane PJ, Wedemeyer H, Pol S, Flisiak R, Poordad F, Chuang WL, Stedman CA, Flamm S, Kwo P, Dore GJ, Sepulveda-Arzola G, Roberts SK, Soto-Malave R, Kaita K, Puoti M, Vierling J, Tam E, Vargas HE, Bruck R, Fuster F, Paik SW, Felizarta F, Kort J, Fu B, Liu R, Ng TI, Pilot-Matias T, Lin CW, Trinh R, Mensa FJ. Glecaprevir-pibrentasvir for 8 or 12 weeks in HCV genotype 1 or 3 infection. N Engl J Med. 2018;378:354–69. https://​doi.​org/​10.​1056/​NEJMoa1702417.CrossRefPubMed

go back to reference Gane E, Svarovskaia ES, Hyland RH, et al. Resistance analysis of treatment-naïve and DAA-experienced genotype 1 patients with and without cirrhosis who received short-duration treatment with sofosbuvir/velpatasvir + GS-9857 [abstract 713], Vol. 62. San Francisco: Hepatology: American Association for the Study of Liver Diseases (AASLD); 2015. Gane E, Svarovskaia ES, Hyland RH, et al. Resistance analysis of treatment-naïve and DAA-experienced genotype 1 patients with and without cirrhosis who received short-duration treatment with sofosbuvir/velpatasvir + GS-9857 [abstract 713], Vol. 62. San Francisco: Hepatology: American Association for the Study of Liver Diseases (AASLD); 2015.

go back to reference Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646–54. https://doi.org/10.1016/j.jhep.2012.11.012.CrossRefPubMed Karino Y, Toyota J, Ikeda K, Suzuki F, Chayama K, Kawakami Y, Ishikawa H, Watanabe H, Hernandez D, Yu F, McPhee F, Kumada H. Characterization of virologic escape in hepatitis C virus genotype 1b patients treated with the direct-acting antivirals daclatasvir and asunaprevir. J Hepatol. 2013;58:646–54. https://​doi.​org/​10.​1016/​j.​jhep.​2012.​11.​012.CrossRefPubMed

go back to reference Wang C, Jia L, O’Boyle DR 2nd, Sun JH, Rigat K, Valera L, Nower P, Huang X, Kienzle B, Roberts S, Gao M, Fridell RA. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother. 2014;58:5155–63. https://doi.org/10.1128/AAC.02788-14.CrossRefPubMedPubMedCentral Wang C, Jia L, O’Boyle DR 2nd, Sun JH, Rigat K, Valera L, Nower P, Huang X, Kienzle B, Roberts S, Gao M, Fridell RA. Comparison of daclatasvir resistance barriers on NS5A from hepatitis C virus genotypes 1 to 6: implications for cross-genotype activity. Antimicrob Agents Chemother. 2014;58:5155–63. https://​doi.​org/​10.​1128/​AAC.​02788-14.CrossRefPubMedPubMedCentral

go back to reference Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, Gillum JM, Pierra C, Standring DN, Seifer M. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2014;58:4431–42. https://doi.org/10.1128/AAC.02777-13.CrossRefPubMedPubMedCentral Bilello JP, Lallos LB, McCarville JF, La Colla M, Serra I, Chapron C, Gillum JM, Pierra C, Standring DN, Seifer M. In vitro activity and resistance profile of samatasvir, a novel NS5A replication inhibitor of hepatitis C virus. Antimicrob Agents Chemother. 2014;58:4431–42. https://​doi.​org/​10.​1128/​AAC.​02777-13.CrossRefPubMedPubMedCentral

go back to reference Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, Yin PD, McPhee F. NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection. The Journal of infectious diseases. 2016;213:206–15. https://doi.org/10.1093/infdis/jiv379.CrossRef Zhou N, Hernandez D, Ueland J, Yang X, Yu F, Sims K, Yin PD, McPhee F. NS5A sequence heterogeneity and mechanisms of daclatasvir resistance in hepatitis C virus genotype 4 infection. The Journal of infectious diseases. 2016;213:206–15. https://​doi.​org/​10.​1093/​infdis/​jiv379.CrossRef

go back to reference Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X. SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–97. https://doi.org/10.1016/S1473-3099(16)00052-9.CrossRef Manns M, Samuel D, Gane EJ, Mutimer D, McCaughan G, Buti M, Prieto M, Calleja JL, Peck-Radosavljevic M, Müllhaupt B, Agarwal K, Angus P, Yoshida EM, Colombo M, Rizzetto M, Dvory-Sobol H, Denning J, Arterburn S, Pang PS, Brainard D, McHutchison JG, Dufour JF, Van Vlierberghe H, van Hoek B, Forns X. SOLAR-2 investigators. Ledipasvir and sofosbuvir plus ribavirin in patients with genotype 1 or 4 hepatitis C virus infection and advanced liver disease: a multicentre, open-label, randomised, phase 2 trial. Lancet Infect Dis. 2016;16:685–97. https://​doi.​org/​10.​1016/​S1473-3099(16)00052-9.CrossRef

go back to reference Schnell G, Tripathi R, Beyer J, et al. Combined resistance, demographic, and phylogenetic analysis of HCV genotype 4-infected patients treated with ombitasvir/paritaprevir/r +/- ribavirin in the PEARL-I and AGATE-I studies [Poster 866. In: American Association for the Study of Liver Diseases (AASLD). Boston (MA): Hepatology; 2016. p. 427–176. Schnell G, Tripathi R, Beyer J, et al. Combined resistance, demographic, and phylogenetic analysis of HCV genotype 4-infected patients treated with ombitasvir/paritaprevir/r +/- ribavirin in the PEARL-I and AGATE-I studies [Poster 866. In: American Association for the Study of Liver Diseases (AASLD). Boston (MA): Hepatology; 2016. p. 427–176.

go back to reference Jacobson IM, Liu EA-A. R, et al. Prevalence and impact of baseline NS5A resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection [abstract LB22]. In: American Association for the Study of Liver Diseases (AASLD). San Francisco: Hepatology; 2015. Jacobson IM, Liu EA-A. R, et al. Prevalence and impact of baseline NS5A resistance associated variants (RAVs) on the efficacy of elbasvir/grazoprevir (EBR/GZR) against GT1a infection [abstract LB22]. In: American Association for the Study of Liver Diseases (AASLD). San Francisco: Hepatology; 2015.

go back to reference Peres-da-Silva A, de Almeida A, Lampe E. NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus. J Antimicrob Chemother. 2015;70:726–30.CrossRef Peres-da-Silva A, de Almeida A, Lampe E. NS5A inhibitor resistance-associated polymorphisms in Brazilian treatment-naive patients infected with genotype 1 hepatitis C virus. J Antimicrob Chemother. 2015;70:726–30.CrossRef

go back to reference Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Talwani R, Serfaty L. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis. Liver Int. 2018. https://doi.org/10.1111/liv.13727.CrossRefPubMed Asselah T, Reesink H, Gerstoft J, de Ledinghen V, Pockros PJ, Robertson M, Hwang P, Asante-Appiah E, Wahl J, Nguyen BY, Barr E, Talwani R, Serfaty L. Efficacy of elbasvir and grazoprevir in participants with hepatitis C virus genotype 4 infection: a pooled analysis. Liver Int. 2018. https://​doi.​org/​10.​1111/​liv.​13727.CrossRefPubMed

go back to reference Hezode C, Colombo M, Spengler U, et al. C-EDGE IBLD: efficacy and safety of elbasvir/grazoprevir in patients with chronic hepatitis c virus infection and inherited blood disorders [Abstract SAT-128]. In: The international liver congress™ EASL—European Association for the Study of the Liver. Barcelona: Journal of Hepatology; 2016. p. S753. Hezode C, Colombo M, Spengler U, et al. C-EDGE IBLD: efficacy and safety of elbasvir/grazoprevir in patients with chronic hepatitis c virus infection and inherited blood disorders [Abstract SAT-128]. In: The international liver congress™ EASL—European Association for the Study of the Liver. Barcelona: Journal of Hepatology; 2016. p. S753.

go back to reference Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR, PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-92. https://doi.org/10.1056/NEJMoa1402338.CrossRefPubMed Ferenci P, Bernstein D, Lalezari J, Cohen D, Luo Y, Cooper C, Tam E, Marinho RT, Tsai N, Nyberg A, Box TD, Younes Z, Enayati P, Green S, Baruch Y, Bhandari BR, Caruntu FA, Sepe T, Chulanov V, Janczewska E, Rizzardini G, Gervain J, Planas R, Moreno C, Hassanein T, Xie W, King M, Podsadecki T, Reddy KR, PEARL-III Study; PEARL-IV Study. ABT-450/r-ombitasvir and dasabuvir with or without ribavirin for HCV. N Engl J Med. 2014;370:1983-92. https://​doi.​org/​10.​1056/​NEJMoa1402338.CrossRefPubMed

go back to reference Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O’Rear JJ, Harrington PR. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology. 2017;152:586–97. https://doi.org/10.1053/j.gastro.2016.10.017.CrossRefPubMed Komatsu TE, Boyd S, Sherwat A, Tracy L, Naeger LK, O’Rear JJ, Harrington PR. Regulatory analysis of effects of hepatitis C virus NS5A polymorphisms on efficacy of elbasvir and grazoprevir. Gastroenterology. 2017;152:586–97. https://​doi.​org/​10.​1053/​j.​gastro.​2016.​10.​017.CrossRefPubMed

go back to reference Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319–27. https://doi.org/10.1016/S2352-3018(15)00114-9.CrossRef Rockstroh JK, Nelson M, Katlama C, Lalezari J, Mallolas J, Bloch M, Matthews GV, Saag MS, Zamor PJ, Orkin C, Gress J, Klopfer S, Shaughnessy M, Wahl J, Nguyen BY, Barr E, Platt HL, Robertson MN, Sulkowski M. Efficacy and safety of grazoprevir (MK-5172) and elbasvir (MK-8742) in patients with hepatitis C virus and HIV co-infection (C-EDGE CO-INFECTION): a non-randomised, open-label trial. Lancet HIV. 2015;2:e319–27. https://​doi.​org/​10.​1016/​S2352-3018(15)00114-9.CrossRef

go back to reference Patel D, Zhao Y, Fabrycki J, et al. Achievement of SVR24 despite the presence of HCV variants resistant to first-generation NS5A inhibitors in genotype-1 hepatitis C patients after 8-week therapy of ACH-3102 in combination with sofosbuvir [Abstract P0805]. In: EASL—the international liver congress 2015 50th annual Meeting of the European association for the Study of the Liver. Vienna, Austria: Journal of Hepatology; 2015. Patel D, Zhao Y, Fabrycki J, et al. Achievement of SVR24 despite the presence of HCV variants resistant to first-generation NS5A inhibitors in genotype-1 hepatitis C patients after 8-week therapy of ACH-3102 in combination with sofosbuvir [Abstract P0805]. In: EASL—the international liver congress 2015 50th annual Meeting of the European association for the Study of the Liver. Vienna, Austria: Journal of Hepatology; 2015.

go back to reference Huang W, Newton A, Frantzell A, et al. Genotypic and phenotypic characterization of clinical HCV NS5A drug resistance [abstract 579]. In: Conference on retroviruses and opportunistic infections (CROI). Boston; 2016. Huang W, Newton A, Frantzell A, et al. Genotypic and phenotypic characterization of clinical HCV NS5A drug resistance [abstract 579]. In: Conference on retroviruses and opportunistic infections (CROI). Boston; 2016.

go back to reference Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075–86. https://doi.org/10.1016/S0140-6736(14)61795-5.CrossRefPubMed Lawitz E, Gane E, Pearlman B, Tam E, Ghesquiere W, Guyader D, Alric L, Bronowicki JP, Lester L, Sievert W, Ghalib R, Balart L, Sund F, Lagging M, Dutko F, Shaughnessy M, Hwang P, Howe AY, Wahl J, Robertson M, Barr E, Haber B. Efficacy and safety of 12 weeks versus 18 weeks of treatment with grazoprevir (MK-5172) and elbasvir (MK-8742) with or without ribavirin for hepatitis C virus genotype 1 infection in previously untreated patients with cirrhosis and patients with previous null response with or without cirrhosis (C-WORTHY): a randomised, open-label phase 2 trial. Lancet. 2015;385:1075–86. https://​doi.​org/​10.​1016/​S0140-6736(14)61795-5.CrossRefPubMed

go back to reference Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A, Kottilil S. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis. 2016;62:280–8. https://doi.org/10.1093/cid/civ874.CrossRef Wilson EM, Kattakuzhy S, Sidharthan S, Sims Z, Tang L, McLaughlin M, Price A, Nelson A, Silk R, Gross C, Akoth E, Mo H, Subramanian GM, Pang PS, McHutchison JG, Osinusi A, Masur H, Kohli A, Kottilil S. Successful retreatment of chronic HCV genotype-1 infection with ledipasvir and sofosbuvir after initial short course therapy with direct-acting antiviral regimens. Clin Infect Dis. 2016;62:280–8. https://​doi.​org/​10.​1093/​cid/​civ874.CrossRef

go back to reference Stirnimann G. Ombitasvir. (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother. 2014;15:2609–22.CrossRef Stirnimann G. Ombitasvir. (ABT-267), a novel NS5A inhibitor for the treatment of hepatitis C. Expert Opin Pharmacother. 2014;15:2609–22.CrossRef

go back to reference Walker J, Crosby R, Wang A, Woldu E, Vamathevan J, Voitenleitner C, You S, Remlinger K, Duan M, Kazmierski W, Hamatake R. Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A. Antimicrob Agents Chemother. 2014;58:38–47. https://doi.org/10.1128/AAC.01363-13.CrossRefPubMedPubMedCentral Walker J, Crosby R, Wang A, Woldu E, Vamathevan J, Voitenleitner C, You S, Remlinger K, Duan M, Kazmierski W, Hamatake R. Preclinical characterization of GSK2336805, a novel inhibitor of hepatitis C virus replication that selects for resistance in NS5A. Antimicrob Agents Chemother. 2014;58:38–47. https://​doi.​org/​10.​1128/​AAC.​01363-13.CrossRefPubMedPubMedCentral

go back to reference Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O’Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96–100. https://doi.org/10.1038/nature08960.CrossRefPubMed Gao M, Nettles RE, Belema M, Snyder LB, Nguyen VN, Fridell RA, Serrano-Wu MH, Langley DR, Sun JH, O’Boyle DR 2nd, Lemm JA, Wang C, Knipe JO, Chien C, Colonno RJ, Grasela DM, Meanwell NA, Hamann LG. Chemical genetics strategy identifies an HCV NS5A inhibitor with a potent clinical effect. Nature. 2010;465:96–100. https://​doi.​org/​10.​1038/​nature08960.CrossRefPubMed

go back to reference Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641–50.CrossRef Fridell RA, Qiu D, Wang C, Valera L, Gao M. Resistance analysis of the hepatitis C virus NS5A inhibitor BMS-790052 in an in vitro replicon system. Antimicrob Agents Chemother. 2010;54:3641–50.CrossRef

go back to reference Dvory-Sobol H, Doehle B, Svarovskaia E, et al. The prevalence of HCV NS5A nucleoside and protease inhibitor resistance associated variants and the effects on treatment with ledipasvir/sofosbuvir + RBV in the phase 3 ION study. In: International workshop on antiviral drug resistance Berlin, German; 2014. Dvory-Sobol H, Doehle B, Svarovskaia E, et al. The prevalence of HCV NS5A nucleoside and protease inhibitor resistance associated variants and the effects on treatment with ledipasvir/sofosbuvir + RBV in the phase 3 ION study. In: International workshop on antiviral drug resistance Berlin, German; 2014.

go back to reference Sulkowski M, Krishnan P, Tripathi R, et al Effect of baseline resistance-associated variants on SVR with the 3D regimen plus RBV [abstract 6LB-3113]. In: 23rd annual conference on retroviruses and opportunistic infections, CROI. Boston, Massachusetts; 2016. Sulkowski M, Krishnan P, Tripathi R, et al Effect of baseline resistance-associated variants on SVR with the 3D regimen plus RBV [abstract 6LB-3113]. In: 23rd annual conference on retroviruses and opportunistic infections, CROI. Boston, Massachusetts; 2016.

go back to reference Fridell RA, Wang C, Sun JH, O’Boyle DR 2nd, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54:1924–35. https://doi.org/10.1002/hep.24594.CrossRefPubMed Fridell RA, Wang C, Sun JH, O’Boyle DR 2nd, Nower P, Valera L, Qiu D, Roberts S, Huang X, Kienzle B, Bifano M, Nettles RE, Gao M. Genotypic and phenotypic analysis of variants resistant to hepatitis C virus nonstructural protein 5A replication complex inhibitor BMS-790052 in humans: in vitro and in vivo correlations. Hepatology. 2011;54:1924–35. https://​doi.​org/​10.​1002/​hep.​24594.CrossRefPubMed

go back to reference Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–28.CrossRef Curry MP, O’Leary JG, Bzowej N, et al. Sofosbuvir and velpatasvir for HCV in patients with decompensated cirrhosis. N Engl J Med. 2015;373:2618–28.CrossRef

go back to reference Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. The prevalence and the effect of HCV NS5A resistance-associated variants in patients with compensated cirrhosis treated with ledipasvir/sofosbuvir ± RBV [abstract P0773]. In: The International liver congress 2015, 50th 24 annual Meeting of the European association for the Study of the Liver (EASL). Vienna, Austria: Journal of Hepatology; 2015. p. S620. Sarrazin C, Dvory-Sobol H, Svarovskaia ES, et al. The prevalence and the effect of HCV NS5A resistance-associated variants in patients with compensated cirrhosis treated with ledipasvir/sofosbuvir ± RBV [abstract P0773]. In: The International liver congress 2015, 50th 24 annual Meeting of the European association for the Study of the Liver (EASL). Vienna, Austria: Journal of Hepatology; 2015. p. S620.

go back to reference Wong KA, Worth A, Martin R, et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57:6333–40.CrossRef Wong KA, Worth A, Martin R, et al. Characterization of Hepatitis C virus resistance from a multiple-dose clinical trial of the novel NS5A inhibitor GS-5885. Antimicrob Agents Chemother. 2013;57:6333–40.CrossRef

go back to reference Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385(9986):2502–9.CrossRef Hezode C, Asselah T, Reddy KR, et al. Ombitasvir plus paritaprevir plus ritonavir with or without ribavirin in treatment-naive and treatment-experienced patients with genotype 4 chronic hepatitis C virus infection (PEARL-I): a randomised, open-label trial. Lancet. 2015;385(9986):2502–9.CrossRef

go back to reference Wang C, Jia L, Huang H, Qiu D, Valera L, Huang X, Sun JH, Nower PT, O’Boyle DR 2nd, Gao M, Fridell RA. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother. 2012;56:1588–90. https://doi.org/10.1128/AAC.06169-11.CrossRefPubMedPubMedCentral Wang C, Jia L, Huang H, Qiu D, Valera L, Huang X, Sun JH, Nower PT, O’Boyle DR 2nd, Gao M, Fridell RA. In vitro activity of BMS-790052 on hepatitis C virus genotype 4 NS5A. Antimicrob Agents Chemother. 2012;56:1588–90. https://​doi.​org/​10.​1128/​AAC.​06169-11.CrossRefPubMedPubMedCentral

go back to reference Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother. 2013;57:611–3.CrossRef Wang C, Valera L, Jia L, Kirk MJ, Gao M, Fridell RA. In vitro activity of daclatasvir on hepatitis C virus genotype 3 NS5A. Antimicrob Agents Chemother. 2013;57:611–3.CrossRef

go back to reference Zhou N, Han Z, Hartman NS, et al. High sustained virologic response rates in patients infected with HCV genotype 2 with baseline NS5A polymorphisms treated with daclatasvir-based regimens [abstract 234]. In: The international liver congress™ EASL—European Association for the Study of the Liver. Spain: Barcelona; 2016. p. S407. Zhou N, Han Z, Hartman NS, et al. High sustained virologic response rates in patients infected with HCV genotype 2 with baseline NS5A polymorphisms treated with daclatasvir-based regimens [abstract 234]. In: The international liver congress™ EASL—European Association for the Study of the Liver. Spain: Barcelona; 2016. p. S407.

go back to reference Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57:13–18.CrossRef Hernandez D, Zhou N, Ueland J, Monikowski A, McPhee F. Natural prevalence of NS5A polymorphisms in subjects infected with hepatitis C virus genotype 3 and their effects on the antiviral activity of NS5A inhibitors. J Clin Virol. 2013;57:13–18.CrossRef

go back to reference Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob Agents Chemother. 2016;60:2954–64. https://doi.org/10.1128/AAC.00051-16.CrossRefPubMedPubMedCentral Lahser FC, Bystol K, Curry S, McMonagle P, Xia E, Ingravallo P, Chase R, Liu R, Black T, Hazuda D, Howe AY, Asante-Appiah E. The combination of grazoprevir, a hepatitis C virus (HCV) NS3/4A protease inhibitor, and elbasvir, an HCV NS5A inhibitor, demonstrates a high genetic barrier to resistance in HCV genotype 1a replicons. Antimicrob Agents Chemother. 2016;60:2954–64. https://​doi.​org/​10.​1128/​AAC.​00051-16.CrossRefPubMedPubMedCentral

go back to reference Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.CrossRef Kowdley KV, Gordon SC, Reddy KR, et al. Ledipasvir and sofosbuvir for 8 or 12 weeks for chronic HCV without cirrhosis. N Engl J Med. 2014;370:1879–88.CrossRef

go back to reference Charlton M, Manns M, Dvory-Sobol H, et al. Resistance analyses for ledipasvir/sofosbuvir-containing regimens in patients infected with chronic HCV who have advanced liver disease or are post liver transplant (SOLAR-1 and -2 studies). In: The international liver congress™ 2016. Spain: EASL. Barcelona; 2016.CrossRef Charlton M, Manns M, Dvory-Sobol H, et al. Resistance analyses for ledipasvir/sofosbuvir-containing regimens in patients infected with chronic HCV who have advanced liver disease or are post liver transplant (SOLAR-1 and -2 studies). In: The international liver congress™ 2016. Spain: EASL. Barcelona; 2016.CrossRef

go back to reference Lawitz E, Freilich B, Link J, et al. A phase 1, randomized, dose: ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. J Viral Hepat. 2015;22:1011–9.CrossRef Lawitz E, Freilich B, Link J, et al. A phase 1, randomized, dose: ranging study of GS-5816, a once-daily NS5A inhibitor, in patients with genotype 1–4 hepatitis C virus. J Viral Hepat. 2015;22:1011–9.CrossRef

go back to reference Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016;64:1049–1056.CrossRef Abergel A, Metivier S, Samuel D, et al. Ledipasvir plus sofosbuvir for 12 weeks in patients with hepatitis C genotype 4 infection. Hepatology. 2016;64:1049–1056.CrossRef

go back to reference Xu S, Rajyaguru S, Hebner C, et al. In vitro selection of resistance to sofosbuvir in GT 2a, 2b, 3a, 4a, 5a and 6a replicons [abstract O_01B]. In: International workshop on hepatitis C resistance and new compounds. Cambridge, USA; 2013. Xu S, Rajyaguru S, Hebner C, et al. In vitro selection of resistance to sofosbuvir in GT 2a, 2b, 3a, 4a, 5a and 6a replicons [abstract O_01B]. In: International workshop on hepatitis C resistance and new compounds. Cambridge, USA; 2013.

go back to reference Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666–74. https://doi.org/10.1093/cid/ciu697.CrossRefPubMed Svarovskaia ES, Dvory-Sobol H, Parkin N, Hebner C, Gontcharova V, Martin R, Ouyang W, Han B, Xu S, Ku K, Chiu S, Gane E, Jacobson IM, Nelson DR, Lawitz E, Wyles DL, Bekele N, Brainard D, Symonds WT, McHutchison JG, Miller MD, Mo H. Infrequent development of resistance in genotype 1–6 hepatitis C virus-infected subjects treated with sofosbuvir in phase 2 and 3 clinical trials. Clin Infect Dis. 2014;59:1666–74. https://​doi.​org/​10.​1093/​cid/​ciu697.CrossRefPubMed

go back to reference Lemm JA, Liu M, Gentles RG, Ding M, Voss S, Pelosi LA, Wang YK, Rigat KL, Mosure KW, Bender JA, Knipe JO, Colonno R, Meanwell NA, Kadow JF, Santone KS, Roberts SB, Gao M. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase. Antimicrob Agents Chemother. 2014;58:3485–95.CrossRef Lemm JA, Liu M, Gentles RG, Ding M, Voss S, Pelosi LA, Wang YK, Rigat KL, Mosure KW, Bender JA, Knipe JO, Colonno R, Meanwell NA, Kadow JF, Santone KS, Roberts SB, Gao M. Preclinical characterization of BMS-791325, an allosteric inhibitor of hepatitis C Virus NS5B polymerase. Antimicrob Agents Chemother. 2014;58:3485–95.CrossRef

go back to reference Devogelaere B, Berke JM, Vijgen L, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Nyanguile O, Tahri A, Amssoms K, Lenz O, Cummings MD, Clayton RF, Vendeville S, Raboisson P, Simmen KA, Fanning GC, Lin TI. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage. Antimicrob Agents Chemother. 2012;56:4676–84. https://doi.org/10.1128/AAC.00245-12.CrossRefPubMedPubMedCentral Devogelaere B, Berke JM, Vijgen L, Dehertogh P, Fransen E, Cleiren E, van der Helm L, Nyanguile O, Tahri A, Amssoms K, Lenz O, Cummings MD, Clayton RF, Vendeville S, Raboisson P, Simmen KA, Fanning GC, Lin TI. TMC647055, a potent nonnucleoside hepatitis C virus NS5B polymerase inhibitor with cross-genotypic coverage. Antimicrob Agents Chemother. 2012;56:4676–84. https://​doi.​org/​10.​1128/​AAC.​00245-12.CrossRefPubMedPubMedCentral

go back to reference Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82. https://doi.org/10.1056/NEJMoa1402869.CrossRefPubMed Poordad F, Hezode C, Trinh R, Kowdley KV, Zeuzem S, Agarwal K, Shiffman ML, Wedemeyer H, Berg T, Yoshida EM, Forns X, Lovell SS, Da Silva-Tillmann B, Collins CA, Campbell AL, Podsadecki T, Bernstein B. ABT-450/r-ombitasvir and dasabuvir with ribavirin for hepatitis C with cirrhosis. N Engl J Med. 2014;370:1973–82. https://​doi.​org/​10.​1056/​NEJMoa1402869.CrossRefPubMed

go back to reference Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Nájera I. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis. 2014;209:668–75. https://doi.org/10.1093/infdis/jit562.CrossRef Tong X, Le Pogam S, Li L, Haines K, Piso K, Baronas V, Yan JM, So SS, Klumpp K, Nájera I. In vivo emergence of a novel mutant L159F/L320F in the NS5B polymerase confers low-level resistance to the HCV polymerase inhibitors mericitabine and sofosbuvir. J Infect Dis. 2014;209:668–75. https://​doi.​org/​10.​1093/​infdis/​jit562.CrossRef

go back to reference Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223–31.CrossRef Sulkowski MS, Eron JJ, Wyles D, Trinh R, Lalezari J, Wang C, Slim J, Bhatti L, Gathe J, Ruane PJ, Elion R, Bredeek F, Brennan R, Blick G, Khatri A, Gibbons K, Hu YB, Fredrick L, Schnell G, Pilot-Matias T, Tripathi R, Da Silva-Tillmann B, McGovern B, Campbell AL, Podsadecki T. Ombitasvir, paritaprevir co-dosed with ritonavir, dasabuvir, and ribavirin for hepatitis C in patients co-infected with HIV-1: a randomized trial. JAMA. 2015;313:1223–31.CrossRef